DOCUMENT AND ENTITY INFORMATION
DOCUMENT AND ENTITY INFORMATION - USD ($) | 12 Months Ended | ||
Dec. 31, 2020 | Feb. 26, 2021 | Jun. 30, 2020 | |
Document And Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2020 | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | Orchid Island Capital, Inc. | ||
Entity Central Index Key | 0001518621 | ||
Entity Current Reporting Status | Yes | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Common Stock Shares Outstanding | 85,121,365 | ||
Trading Symbol | ORC | ||
Security Exchange Name | NYSE | ||
Security 12(b) Title | Common Stock, $0.01 par value | ||
Interactive Data Current | Yes | ||
Document Transition Report | false | ||
City Area Code | 772 | ||
Local Phone Number | 231-1400 | ||
Entity Address Line 1 | 3305 Flamingo Drive | ||
Entity Address City or Town | Vero Beach | ||
Entity Address State or Province | FL | ||
Entity Postal Zip Code | 32963 | ||
Entity Incorporation, State Country Name | MD | ||
Entity File Number | 001-35236 | ||
Entity Tax ID Number | 27-3269228 | ||
DocumentAnnualReport | true | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Public Float | $ 298,895,633 | ||
DocumentsIncorporatedByReferenceTextBlock | Portions of the Registrant's definitive Proxy Statement, to be issued in connection with the 2021 Annual Meeting of Stockholders of the Registrant, are incorporated by reference into Part III of this Annual Report on Form 10-K. |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Mortgage-backed securities, at fair value | ||
Pledged to counterparties | $ 3,719,906 | $ 3,584,354 |
Unpledged | 6,989 | 6,567 |
Total mortgage-backed securities | 3,726,895 | 3,590,921 |
Cash and cash equivalents | 220,143 | 193,770 |
Restricted cash | 79,363 | 84,885 |
Accrued interest receivable | 9,721 | 12,404 |
Derivative Assets | 20,999 | 0 |
Receivable for securities sold, pledged to counterparties | 414 | 0 |
Other assets | 516 | 100 |
Total Assets | 4,058,051 | 3,882,080 |
Liabilities | ||
Outstanding repurchase obligations | 3,595,586 | 3,448,106 |
Dividends Payable | 4,970 | 5,045 |
Derivitive Liabilities | 33,227 | 20,658 |
Accrued interest payable | 1,157 | 11,101 |
Due to affiliates | 632 | 622 |
Other Liabilities | 7,188 | 1,041 |
Total Liabilities | 3,642,760 | 3,486,573 |
Stockholders' Equity | ||
Preferred stock, $0.01 par value | 0 | 0 |
Common Stock, $0.01 par value | 761 | 631 |
Additional paid in capital | 432,524 | 414,998 |
Accumulated deficit | (17,994) | (20,122) |
Total Stockholders Equity | 415,291 | 395,507 |
Total Liabilities and Stockholders Equity | 4,058,051 | 3,882,080 |
Residential Mortgage Backed Securities [Member] | ||
Mortgage-backed securities, at fair value | ||
Accrued interest receivable | $ 9,636 | $ 12,367 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares | Dec. 31, 2020 | Dec. 31, 2019 |
Statement Of Financial Position [Abstract] | ||
Preferred Stock, par value (in dollars per share) | $ 0.01 | |
Preferred Shares Authorized | 100,000,000 | |
Common Stock, par value (in dollars per share) | $ 0.01 | |
Common Stock Shares Authorized | 500,000,000 | |
Common Shares Issued | 76,073,317 | 63,061,781 |
Common Shares Outstanding | 76,073,000 | 63,062,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Interest income | $ 116,045 | $ 142,324 | $ 154,581 |
Interest expense | 25,056 | 83,666 | 70,360 |
Net interest income | 90,989 | 58,658 | 84,221 |
Realized gains (losses) on mortgage-backed securities | (24,986) | (10,877) | (30,289) |
Unrealized gains (losses) on mortgage-backed securities | 25,761 | 38,045 | (110,668) |
(Losses) gains on derivative instruments | (79,092) | (51,176) | 24,311 |
Net portfolio income | 12,672 | 34,650 | (32,425) |
Expenses | |||
Management Fee Expense | 5,281 | 5,528 | 6,204 |
Allocated Overhead | 1,514 | 1,380 | 1,567 |
Compensation and related benefits | 38 | 115 | 407 |
Directors fees and liability insurance | 998 | 998 | 968 |
Audit, legal and other professional fees | 1,045 | 1,105 | 851 |
Direct REIT operating expenses | 1,057 | 997 | 1,631 |
Other administrative | 611 | 262 | 334 |
Total expenses | 10,544 | 10,385 | 11,962 |
Net income (loss) | $ 2,128 | $ 24,265 | $ (44,387) |
Basic and diluted net income (loss) per share | |||
Basic and Diluted | $ 0.03 | $ 0.43 | $ (0.85) |
Weighted Average Shares Outstanding | |||
Weighted Average Shares - Basic and Diluted | 67,210,815 | 56,328,027 | 52,198,175 |
CONSOLIDATED STATEMENT OF STOCK
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY, (Unaudited) - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid In Capital [Member] | Retained Earnings [Member] |
Balances at Dec. 31, 2017 | $ 462,211 | $ 531 | $ 461,680 | $ 0 |
Increase (Decrease) in Stockholders' Equity | ||||
Net income | (44,387) | 0 | 0 | (44,387) |
Cash dividend declared | 55,814 | 0 | 55,814 | 0 |
Amortization of stock based compensation | 492 | 0 | 492 | 0 |
Stock Repurchased and Retired During Period, Value | (26,423) | (40) | (26,383) | 0 |
Balances at Dec. 31, 2018 | $ 336,079 | 491 | 379,975 | (44,387) |
Common Stock Shares Outstanding, Beginning Balance at Dec. 31, 2017 | 53,062,000 | |||
Increase (Decrease) in Stockholders' Equity | ||||
Stock Issued During Period Shares Share Based Compensation | 49,000 | |||
Stock Repurchased and Retired During Period, Shares | 3,979,000 | |||
Common Stock Shares Outstanding, Ending Balance at Dec. 31, 2018 | 49,132,000 | |||
Increase (Decrease) in Stockholders' Equity | ||||
Net income | $ 24,265 | 0 | 0 | 24,265 |
Cash dividend declared | 54,421 | 0 | 54,421 | 0 |
Issuance of common stock pursuant to public offerings, net | 92,314 | 145 | 92,169 | 0 |
Amortization of stock based compensation | 294 | 0 | 294 | 0 |
Stock Repurchased and Retired During Period, Value | (3,024) | (5) | (3,019) | 0 |
Balances at Dec. 31, 2019 | $ 395,507 | 631 | 414,998 | (20,122) |
Increase (Decrease) in Stockholders' Equity | ||||
Stock Issued During Period Shares New Issues | 14,377,126 | |||
Stock Issued During Period Shares Share Based Compensation | 23,000 | |||
Stock Repurchased and Retired During Period, Shares | 470,000 | |||
Common Stock Shares Outstanding, Ending Balance at Dec. 31, 2019 | 63,062,000 | |||
Increase (Decrease) in Stockholders' Equity | ||||
Net income | $ 2,128 | 0 | 0 | 2,128 |
Cash dividend declared | 53,570 | 0 | 53,570 | 0 |
Issuance of common stock pursuant to public offerings, net | 71,050 | 130 | 70,920 | 0 |
Amortization of stock based compensation | 244 | 0 | 244 | 0 |
Stock Repurchased and Retired During Period, Value | (68) | 0 | (68) | 0 |
Balances at Dec. 31, 2020 | $ 415,291 | $ 761 | $ 432,524 | $ (17,994) |
Increase (Decrease) in Stockholders' Equity | ||||
Stock Issued During Period Shares New Issues | 13,019,240 | |||
Stock Issued During Period Shares Share Based Compensation | 12,000 | |||
Stock Repurchased and Retired During Period, Shares | 19,891 | |||
Common Stock Shares Outstanding, Ending Balance at Dec. 31, 2020 | 76,073,000 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS, (Unaudited) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES | |||
Net income (loss) | $ 2,128 | $ 24,265 | $ (44,387) |
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | |||
Stock based compensation and equity plan amortization | 244 | 294 | 492 |
Realized and unrealized (gains) losses on mortgage-backed securities | (775) | (27,168) | 140,957 |
Derivative, Gain (Loss) on Derivative, Net | 58,891 | 45,207 | (4,052) |
Changes in operating assets and liabilities | |||
Accrued interest receivable | 2,683 | 837 | 1,203 |
Other assets | (446) | 80 | (3) |
Accrued interest payable | (9,944) | 4,656 | (71) |
Other liabilities | 2,583 | 22 | 4 |
Due to affiliates | 10 | (32) | (143) |
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES | 55,374 | 48,161 | 94,000 |
From mortgage-backed securities investments | |||
Purchases | (4,859,434) | (4,241,822) | (3,893,828) |
Sales | 4,200,536 | 3,321,206 | 3,885,817 |
Principal repayments | 523,699 | 594,833 | 373,934 |
Proceeds from U.S. Treasury Securities | 139,712 | 0 | 0 |
Payments on U.S. Treasury Securities | 139,807 | 0 | 0 |
Net payments on reverse repurchase agreements | 30 | 0 | 0 |
Payments on net settlement of to-be-announced securities | (881) | (8,423) | 7,292 |
Purchase of interest rate swaptions, net of margin cash received | 63,195 | 20,600 | (6,805) |
NET CASH USED IN INVESTING ACTIVITIES | (199,340) | (354,806) | 380,020 |
CASH FLOWS FROM FINANCING ACTIVITIES | |||
Proceeds from repurchase agreements | 33,140,625 | 45,595,010 | 52,096,292 |
Principal payments on repurchase agreements | (32,993,145) | (45,171,956) | (52,605,026) |
Cash dividends | (53,645) | (53,307) | (59,312) |
Proceeds From Issuance Of Common Stock, net of issuance costs | 71,050 | 92,314 | 0 |
Payments For Repurchase Of Common Stock | 68 | 3,024 | 26,423 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 164,817 | 459,037 | (594,469) |
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 20,851 | 152,392 | (120,449) |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period | 278,655 | 126,263 | 246,712 |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period | 299,506 | 278,655 | 126,263 |
Cash paid during the period for: | |||
Interest Paid | 35,000 | 79,010 | 70,431 |
SUPPLEMENTAL DISCLOSURES OF NONCASH FINANCING ACTIVITIES: | |||
Securities Sold Settled In Later Period | 0 | 0 | 220,655 |
Interest Rate Swaption [Member] | |||
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | |||
Derivative, Gain (Loss) on Derivative, Net | (2,972) | (1,379) | 1,502 |
Swap [Member] | |||
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | |||
Derivative, Gain (Loss) on Derivative, Net | (59,055) | (39,471) | (1,027) |
TBA Contracts [Member] | |||
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | |||
Derivative, Gain (Loss) on Derivative, Net | 3,231 | (4,357) | (4,527) |
US Treasury Securities [Member] | |||
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | |||
Derivative, Gain (Loss) on Derivative, Net | $ (95) | $ 0 | $ 0 |
ORGANIZATION AND SIGNIFICANT AC
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization and Significant Accounting Policies | NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Business Description Orchid Island Capital, Inc. (“Orchid” or the “Company”), was incorporated in Maryland on August 17, 2010 for the purpose of creating and managing a leveraged investment portfolio consisting of residential mortgage-backed securities (“RMBS”). From incorporation to February 20, 2013 Orchid was a wholly owned subsidiary of Bimini Capital Management, Inc. (“Bimini”). Orchid began operations on November 24, 2010 (the date of commencement of operations). From incorporation through November 24, 2010, Orchid’s only activity was the issuance of common stock to Bimini. On August 2, 2017, Orchid entered into an equity distribution agreement (the “August 2017 Equity Distribution Agreement”) with two sales agents pursuant to which the Company could offer and sell, from time to time, up to an aggregate amount of $ 125,000,000 of shares of the Company’s common stock in transactions that were deemed to be “at the market” offerings and privately negotiated transactions. The Company issued a total of 15,123,178 shares under the August 2017 Equity Distribution Agreement for aggregate gross proceeds of approximately $ 125.0 million, and net proceeds of approximately $ 123.1 million, net of commissions and fees, prior to its termination in July 2019. On July 30, 2019, Orchid entered into an underwriting agreement (the “2019 Underwriting Agreement”) with Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives of the underwriters named therein, relating to the offer and sale of 7,000,000 shares of the Company’s common stock at a price to the public of $ 6.55 per share. The underwriters purchased the shares pursuant to the 2019 Underwriting Agreement at a price of $ 6.3535 per share. The closing of the offering of 7,000,000 shares of common stock occurred on August 2, 2019, with net proceeds to the Company of approximately $ 44.2 million after deduction of underwriting discounts and commissions and other estimated offering expenses. On January 23, 2020, Orchid entered into an equity distribution agreement (the “January 2020 Equity Distribution Agreement”) with three sales agents pursuant to which the Company could offer and sell, from time to time, up to an aggregate amount of $ 200,000,000 of shares of the Company’s common stock in transactions that were deemed to be “at the market” offerings and privately negotiated transactions. The Company issued a total of 3,170,727 shares under the January 2020 Equity Distribution Agreement for aggregate gross proceeds of $ 19.8 million, and net proceeds of approximately $ 19.4 million, net of commissions and fees, prior to its termination in August 2020. On August 4, 2020, Orchid entered into an equity distribution agreement (the “August 2020 Equity Distribution Agreement”) with four sales agents pursuant to which the Company may offer and sell, from time to time, up to an aggregate amount of $ 150,000,000 of shares of the Company’s common stock in transactions that are deemed to be “at the market” offerings and privately negotiated transactions. Through December 31, 2020, the Company issued a total of 9,848,513 shares under the August 2020 Equity Distribution Agreement for aggregate gross proceeds of approximately $ 52.5 million, and net proceeds of approximately $ 51.6 million, net of commissions and fees. Subsequent to December 31, 2020 through February 26, 2021, the Company issued a total of 308,048 shares under the August 2020 Equity Distribution Agreement for aggregate gross proceeds of approximately $ 1.6 million. COVID-19 Impact Beginning in mid-March 2020, the global pandemic associated with the novel coronavirus (“COVID-19”) and related economic conditions began to impact our financial position and results of operations. As a result of the economic, health and market turmoil brought about by COVID-19, the Agency RMBS market experienced severe dislocations. This resulted in falling prices of our assets and increased margin calls from our repurchase agreement lenders. Further, as interest rates declined, we faced additional margin calls related to our various hedge positions. In order to maintain sufficient cash and liquidity, reduce risk and satisfy margin calls, we were forced to sell assets at levels significantly below their carrying values and closed several hedge positions. During this period, we sold approximately $ 1.1 billion of Agency RMBS, resulting in losses of approximately $ 31.4 million. Also during this period, we terminated interest rate swap positions with an aggregate notional value of $ 860.0 million and incurred approximately $ 45.0 million in fair value losses on the positions through the date of the respective terminations. The Agency RMBS market largely stabilized after the Federal Reserve announced on March 23, 2020 that it would purchase Agency RMBS and U.S. Treasuries in the amounts needed to support smooth market functioning. As of December 31, 2020, we had timely satisfied all margin calls. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may continue to have adverse effects on the Company’s results of future operations, financial position, and liquidity in fiscal year 2021. In addition, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which has provided billions of dollars of relief to individuals, businesses, state and local governments, and the health care system suffering the impact of the pandemic, including mortgage loan forbearance and modification programs to qualifying borrowers who may have difficulty making their loan payments. As certain time limits imposed in the CARES Act programs began to expire, on December 27, 2020, President Trump signed into law an additional coronavirus aid package as part of the Consolidated Appropriations Act, 2021, providing for extensions of many of the CARES Act policies and programs as well as billions of dollars of additional relief. The Company has evaluated the provisions of the CARES Act and the Consolidated Appropriations Act, 2021 and has determined that it will not have a material effect on the Company’s business, results of operations and financial condition. Basis of Presentation and Use of Estimates The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates affecting the accompanying financial statements are the fair values of RMBS and derivatives. Management believes the estimates and assumptions underlying the financial statements are reasonable based on the information available as of December 31, 2020; however, uncertainty over the ultimate impact that COVID-19 will have on the global economy generally, and on Orchid’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would beabsent the current and potential impacts of COVID-19. Variable Interest Entities (VIEs) We obtain interests in VIEs through our investments in mortgage-backed securities. Our interests in these VIEs are passive in nature and are not expected to result in us obtaining a controlling financial interest in these VIEs in the future. As a result, we do not consolidate these VIEs and we account for our interest in these VIEs as mortgage-backed securities. See Note 2 for additional information regarding our investments in mortgage-backed securities. Our maximum exposure to loss for these VIEs is the carrying value of the mortgage-backed securities. Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents include cash on deposit with financial institutions and highly liquid investments with original maturities of three months or less at the time of purchase. Restricted cash includes cash pledged as collateral for repurchase agreements and other borrowings, and interest rate swaps and other derivative instruments. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. (in thousands) December 31, 2020 December 31, 2019 Cash and cash equivalents $ 220,143 $ 193,770 Restricted cash 79,363 84,885 Total cash, cash equivalents and restricted cash $ 299,506 $ 278,655 The Company maintains cash balances at three banks and excess margin on account with two exchange clearing members. At times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances. The Federal Deposit Insurance Corporation insures eligible accounts up to $250,000 per depositor at each financial institution. Restricted cash balances are uninsured, but are held in separate customer accounts that are segregated from the general funds of the counterparty. The Company limits uninsured balances to only large, well-known banks and exchange clearing members and believes that it is not exposed to any significant credit risk on cash and cash equivalents or restricted cash balances. Mortgage-Backed Securities The Company invests primarily in mortgage pass-through residential mortgage backed certificates issued by Freddie Mac, Fannie Mae or Ginnie Mae (“RMBS”), collateralized mortgage obligations (“CMOs”), interest-only (“IO”) securities and inverse interest-only (“IIO”) securities representing interest in or obligations backed by pools of RMBS. We refer to RMBS and CMOs as PT RMBS. We refer to IO and IIO securities as structured RMBS. The Company has elected to account for its investment in RMBS under the fair value option. Electing the fair value option requires the Company to record changes in fair value in the statement of operations, which, in management’s view, more appropriately reflects the results of our operations for a particular reporting period and is consistent with the underlying economics and how the portfolio is managed. The Company records RMBS transactions on the trade date. Security purchases that have not settled as of the balance sheet date are included in the RMBS balance with an offsetting liability recorded, whereas securities sold that have not settled as of the balance sheet date are removed from the RMBS balance with an offsetting receivable recorded. Fair value is defined as the price that would be received to sell the asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. The fair value measurement assumes that the transaction to sell the asset or transfer the liability either occurs in the principal market for the asset or liability, or in the absence of a principal market, occurs in the most advantageous market for the asset or liability. Estimated fair values for RMBS are based on independent pricing sources and/or third party broker quotes, when available. Income on PT RMBS securities is based on the stated interest rate of the security. Premiums or discounts present at the date of purchase are not amortized. Premium lost and discount accretion resulting from monthly principal repayments are reflected in unrealized gains (losses) on RMBS in the statements of operations. For IO securities, the income is accrued based on the carrying value and the effective yield. The difference between income accrued and the interest received on the security is characterized as a return of investment and serves to reduce the asset’s carrying value. At each reporting date, the effective yield is adjusted prospectively for future reporting periods based on the new estimate of prepayments and the contractual terms of the security. For IIO securities, effective yield and income recognition calculations also take into account the index value applicable to the security. Changes in fair value of RMBS during each reporting period are recorded in earnings and reported as unrealized gains or losses on mortgage-backed securities in the accompanying statements of operations. Derivative Financial Instruments The Company uses derivative and other hedging instruments to manage interest rate risk, facilitate asset/liability strategies and manage other exposures, and it may continue to do so in the future. The principal instruments that the Company has used to date are Treasury Note (“T-Note”), Fed Funds and Eurodollar futures contracts, short positions in U.S. Treasury securities, interest rate swaps, options to enter in interest rate swaps (“interest rate swaptions”) and “to-be-announced” (“TBA”) securities transactions, but the Company may enter into other derivative and other hedging instruments in the future. The Company accounts for TBA securities as derivative instruments. Gains and losses associated with TBA securities transactions are reported in gain (loss) on derivative instruments in the accompanying statements of operations. Derivative and other hedging instruments are carried at fair value, and changes in fair value are recorded in earnings for each period. The Company’s derivative financial instruments are not designated as hedge accounting relationships, but rather are used as economic hedges of its portfolio assets and liabilities. Holding derivatives creates exposure to credit risk related to the potential for failure on the part of counterparties and exchanges to honor their commitments. In the event of default by a counterparty, the Company may have difficulty recovering its collateral and may not receive payments provided for under the terms of the agreement. The Company’s derivative agreements require it to post or receive collateral to mitigate such risk. In addition, the Company uses only registered central clearing exchanges and well-established commercial banks as counterparties, monitors positions with individual counterparties and adjusts posted collateral as required. Financial Instruments The fair value of financial instruments for which it is practicable to estimate that value is disclosed, either in the body of the financial statements or in the accompanying notes. RMBS, Eurodollar, Fed Funds and T-Note futures contracts, interest rate swaps, interest rate swaptions and TBA securities are accounted for at fair value in the balance sheets. The methods and assumptions used to estimate fair value for these instruments are presented in Note 13 of the financial statements. The estimated fair value of cash and cash equivalents, restricted cash, accrued interest receivable, receivable for securities sold, other assets, due to affiliates, repurchase agreements, payable for unsettled securities purchased, accrued interest payable and other liabilities generally approximates their carrying values as of December 31, 2020 and December 31, 2019 due to the short-term nature of these financial instruments. Repurchase Agreements The Company finances the acquisition of the majority of its RMBS through the use of repurchase agreements under master repurchase agreements. Repurchase agreements are accounted for as collateralized financing transactions, which are carried at their contractual amounts, including accrued interest, as specified in the respective agreements. Reverse Repurchase Agreements and Obligations to Return Securities Borrowed under Reverse Repurchase Agreements The Company borrows securities to cover short sales of U.S. Treasury securities through reverse repurchase transactions under our master repurchase agreements. We account for these as securities borrowing transactions and recognize an obligation to return the borrowed securities at fair value on the balance sheet based on the value of the underlying borrowed securities as of the reporting date. The securities received as collateral in connection with our reverse repurchase agreements mitigate our credit risk exposure to counterparties. Our reverse repurchase agreements typically have maturities of 30 days or less. Manager Compensation The Company is externally managed by Bimini Advisors, LLC (the “Manager” or “Bimini Advisors”), a Maryland limited liability company and wholly-owned subsidiary of Bimini. The Company’s management agreement with the Manager provides for payment to the Manager of a management fee and reimbursement of certain operating expenses, which are accrued and expensed during the period for which they are earned or incurred. Refer to Note 14 for the terms of the management agreement. Earnings Per Share Basic earnings per share (“EPS”) is calculated as net income or loss attributable to common stockholders divided by the weighted average number of shares of common stock outstanding or subscribed during the period. Diluted EPS is calculated using the treasury stock or two-class method, as applicable, for common stock equivalents, if any. However, the common stock equivalents are not included in computing diluted EPS if the result is anti-dilutive. Income Taxes Orchid has qualified and elected to be taxed as a REIT under the Code. REITs are generally not subject to federal income tax on their REIT taxable income provided that they distribute to their stockholders at least 90% of their REIT taxable income on an annual basis. In addition, a REIT must meet other provisions of the Code to retain its tax status. Orchid assesses the likelihood, based on their technical merit, that uncertain tax positions will be sustained upon examination based on the facts, circumstances and information available at the end of each period. All of Orchid’s tax positions are categorized as highly certain. There is no accrual for any tax, interest or penalties related to Orchid’s tax position assessment. The measurement of uncertain tax positions is adjusted when new information is available, or when an event occurs that requires a change. Recent Accounting Pronouncements On January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires credit losses on most financial assets measured at amortized cost and certain other instruments to be measured using an expected credit loss model (referred to as the current expected credit loss model). The Company’s adoption of this ASU did not have a material effect on its financial statements as its financial assets were already measured at fair value through earnings. In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 provides optional expedients and exceptions to GAAP requirements for modifications on debt instruments, leases, derivatives, and other contracts, related to the expected market transition from the London Interbank Offered Rate (“LIBOR”), and certain other floating rate benchmark indices, or collectively, IBORs, to alternative reference rates. ASU 2020-04 generally considers contract modifications related to reference rate reform to be an event that does not require contract remeasurement at the modification date nor a reassessment of a previous accounting determination. The guidance in ASU 2020-04 is optional and may be elected over time, through December 31, 2022, as reference rate reform activities occur. The Company does not believe the adoption of this ASU will have a material impact on its financial statements. In January 2021, the FASB issued ASU 2021-01 “Reference Rate Reform (Topic 848). ASU 2021-01 expands the scope of ASC 848 to include all affected derivatives and give market participants the ability to apply certain aspects of the contract modification and hedge accounting expedients to derivative contracts affected by the discounting transition. In addition, ASU 2021-01 adds implementation guidance to permit a company to apply certain optional expedients to modifications of interest rate indexes used for margining, discounting or contract price alignment of certain derivatives as a result of reference rate reform initiatives and extends optional expedients to account for a derivative contract modified as a continuation of the existing contract and to continue hedge accounting when certain critical terms of a hedging relationship change to modifications made as part of the discounting transition. The guidance in ASU 2021-01 is effective immediately and available generally through December 31, 2022, as reference rate reform activities occur. The Company does not believe the adoption of this ASU will have a material impact on its financial statements. |
MORTGAGE-BACKED SECURITIES
MORTGAGE-BACKED SECURITIES | 12 Months Ended |
Dec. 31, 2020 | |
Investments, Debt and Equity Securities [Abstract] | |
Mortgage-Backed Securities | NOTE 2. MORTGAGE-BACKED SECURITIES The following table presents the Company’s RMBS portfolio as of December 31, 2020 and December 31, 2019: (in thousands) December 31, 2020 December 31, 2019 Pass-Through RMBS Certificates: Adjustable-rate Mortgages $ - $ 1,014 Fixed-rate Mortgages 3,560,746 3,206,013 Fixed-rate CMOs 137,453 299,205 Total Pass-Through Certificates 3,698,199 3,506,232 Structured RMBS Certificates: Interest-Only Securities 28,696 60,986 Inverse Interest-Only Securities - 23,703 Total Structured RMBS Certificates 28,696 84,689 Total $ 3,726,895 $ 3,590,921 |
REPURCHASE AGREEMENTS AND OTHER
REPURCHASE AGREEMENTS AND OTHER BORROWINGS | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of Repurchase Agreements [Abstract] | |
Repurchase Agreements and Other Borrowings | NOTE 3. REPURCHASE AGREEMENTS The Company pledges certain of its RMBS as collateral under repurchase agreements with financial institutions. Interest rates are generally fixed based on prevailing rates corresponding to the terms of the borrowings, and interest is generally paid at the termination of a borrowing. If the fair value of the pledged securities declines, lenders will typically require the Company to post additional collateral or pay down borrowings to re-establish agreed upon collateral requirements, referred to as "margin calls." Similarly, if the fair value of the pledged securities increases, lenders may release collateral back to the Company. As of December 31, 2020, the Company had met all margin call requirements. As of December 31, 2020 and 2019, the Company’s repurchase agreements had remaining maturities as summarized below: ($ in thousands) OVERNIGHT BETWEEN 2 BETWEEN 31 GREATER (1 DAY OR AND AND THAN LESS) 30 DAYS 90 DAYS 90 DAYS TOTAL December 31, 2020 Fair market value of securities pledged, including accrued interest receivable $ - $ 2,112,969 $ 1,560,798 $ 55,776 $ 3,729,543 Repurchase agreement liabilities associated with these securities $ - $ 2,047,897 $ 1,494,500 $ 53,189 $ 3,595,586 Net weighted average borrowing rate - 0.23% 0.22% 0.30% 0.23% December 31, 2019 Fair market value of securities pledged, including accrued interest receivable $ - $ 2,470,263 $ 1,005,517 $ 120,941 $ 3,596,721 Repurchase agreement liabilities associated with these securities $ - $ 2,361,378 $ 964,368 $ 122,360 $ 3,448,106 Net weighted average borrowing rate - 2.04% 1.94% 2.60% 2.03% In addition, cash pledged to counterparties as collateral for repurchase agreements was approximately $ 58.8 million and $ 65.9 million as of December 31, 2020 and 2019, respectively. If, during the term of a repurchase agreement, a lender files for bankruptcy, the Company might experience difficulty recovering its pledged assets , which could result in an unsecured claim against the lender for the difference between the amount loaned to the Company plus interest due to the counterparty and the fair value of the collateral pledged to such lender , including the accrued interest receivable and cash posted by the Company as collateral. At December 31, 2020, the Company had an aggregate amount at risk (the difference between the amount loaned to the Company, including interest payable and securities posted by the counterparty (if any), and the fair value of securities and cash pledged (if any), including accrued interest on such securities) with all counterparties of approximately $ 176.3 million. The Company did not have an amount at risk with any individual counterparty greater than 10% of the Company’s equity at December 31, 2020 and 2019 |
DERIVATIVE FINANCIAL INSTRUMENT
DERIVATIVE FINANCIAL INSTRUMENTS | 12 Months Ended |
Dec. 31, 2020 | |
Derivative Financial Instruments [Abstract] | |
Derivative Financial Instruments | NOTE 4. DERIVATIVE AND OTHER HEDGING INSTRUMENTS The table below summarizes fair value information about our derivative and other hedging instruments assets and liabilities as of December 31, 2020 and 2019. (in thousands) Derivative and Other Hedging Instruments Balance Sheet Location December 31, 2020 December 31, 2019 Assets Interest rate swaps Derivative assets, at fair value $ 7 $ - Payer swaptions (long positions) Derivative assets, at fair value 17,433 - TBA securities Derivative assets, at fair value 3,559 - Total derivative assets, at fair value $ 20,999 $ - Liabilities Interest rate swaps Derivative liabilities, at fair value $ 24,711 $ 20,146 Payer swaptions (short positions) Derivative liabilities, at fair value 7,730 - TBA securities Derivative liabilities, at fair value 786 512 Total derivative liabilities, at fair value $ 33,227 $ 20,658 Margin Balances Posted to (from) Counterparties Futures contracts Restricted cash $ 489 $ 1,338 TBA securities Restricted cash 284 246 TBA securities Other liabilities ( 2,520) - Interest rate swaption contracts Other liabilities ( 3,563) - Interest rate swap contracts Restricted cash 19,761 17,450 Total margin balances on derivative contracts $ 14,451 $ 19,034 Eurodollar, Fed Funds and T-Note futures are cash settled futures contracts on an interest rate, with gains and losses credited or charged to the Company’s cash accounts on a daily basis. A minimum balance, or “margin”, is required to be maintained in the account on a daily basis. The tables below present information related to the Company’s Eurodollar and T-Note futures positions at December 31, 2020 and 2019. ($ in thousands) December 31, 2020 Average Weighted Weighted Contract Average Average Notional Entry Effective Open Expiration Year Amount Rate Rate Equity (1) Eurodollar Futures Contracts (Short Positions) 2021 $ 50,000 1.03% 0.18% $ ( 424) U.S. Treasury Note Futures Contracts (Short Position) (2) March 2021 5-year T-Note futures (Mar 2021 - Mar 2026 Hedge Period) $ 69,000 0.72% 0.67% $ ( 186) ($ in thousands) December 31, 2019 Average Weighted Weighted Contract Average Average Notional Entry Effective Open Expiration Year Amount Rate Rate Equity (1) Eurodollar Futures Contracts (Short Positions) 2020 $ 500,000 2.97% 1.67% $ ( 6,505) U.S. Treasury Note Futures Contracts (Short Position) (2) March 2020 5 year T-Note futures (Mar 2020 - Mar 2025 Hedge Period) $ 69,000 1.96% 2.06% $ 302 ($ in thousands) Average Net Fixed Average Estimated Average Notional Pay Receive Fair Maturity Amount Rate Rate Value (Years) December 31, 2020 Expiration > 3 to ≤ 5 years $ 620,000 1.29% 0.22% $ ( 23,760) 3.6 Expiration > 5 years $ 200,000 0.67% 0.23% $ ( 944) 6.4 $ 820,000 1.14% 0.23% $ ( 24,704) 4.3 December 31, 2019 Expiration > 1 to ≤ 3 years $ 360,000 2.05% 1.90% $ ( 3,680) 2.3 Expiration > 3 to ≤ 5 years 910,000 2.03% 1.93% ( 16,466) 4.4 $ 1,270,000 2.03% 1.92% $ ( 20,146) 3.8 The table below presents information related to the Company’s interest rate swaption positions at December 31, 2020. There were no open swaption positions at December 31, 2019. ($ in thousands) Option Underlying Swap Weighted Average Weighted Average Average Adjustable Average Fair Months to Notional Fixed Rate Term Expiration Cost Value Expiration Amount Rate (LIBOR) (Years) December 31, 2020 Payer Swaptions (long positions) ≤ 1 year $ 3,450 $ 5 2.5 500,000 0.95% 3 Month 4.0 > 1 year ≤ 2 years 13,410 17,428 17.4 675,000 1.49% 3 Month 12.8 $ 16,860 $ 17,433 11.0 $ 1,175,000 1.26% 3 Month 9.0 Payer Swaptions (short positions) ≤ 1 year $ ( 4,660) $ ( 7,730) 5.4 $ 507,700 1.49% 3 Month 12.8 The following table summarizes our contracts to purchase and sell TBA securities as of December 31, 2020 and 2019. ($ in thousands) Notional Net Amount Cost Market Carrying Long (Short) (1) Basis (2) Value (3) Value (4) December 31, 2020 30-Year TBA securities: 2.0% $ 465,000 $ 479,531 $ 483,090 $ 3,559 3.0% ( 328,000) ( 342,896) ( 343,682) ( 786) Total $ 137,000 $ 136,635 $ 139,408 $ 2,773 December 31, 2019 30-Year TBA securities: 4.5% $ ( 300,000) $ ( 315,426) $ ( 315,938) $ ( 512) Total $ ( 300,000) $ ( 315,426) $ ( 315,938) $ ( 512) Gain (Loss) From Derivative and Other Hedging Instruments, Net The table below presents the effect of the Company’s derivative and other hedging instruments on the statements of operations for the years ended December 31, 2020, 2019 and 2018. (in thousands) 2020 2019 2018 Eurodollar futures contracts (short positions) $ ( 8,337) $ ( 13,860) $ 7,170 U.S. Treasury Note futures contracts (short position) ( 4,707) ( 5,175) 5,507 Fed Funds futures contracts (short positions) - 177 - Interest rate swaps ( 66,212) ( 26,582) 8,609 Receiver swaptions - - 105 Payer swaptions (long positions) 98 ( 1,379) ( 1,607) Payer swaptions (short positions) ( 3,070) - - TBA securities (short positions) ( 6,719) ( 6,264) 4,327 TBA securities (long positions) 9,950 1,907 200 U.S. Treasury securities (short positions) ( 95) - - Total $ ( 79,092) $ ( 51,176) $ 24,311 Credit Risk-Related Contingent Features The use of derivatives and other hedging instruments creates exposure to credit risk relating to potential losses that could be recognized in the event that the counterparties to these instruments fail to perform their obligations under the contracts. We minimize this risk by limiting our counterparties for instruments which are not centrally cleared on a registered exchange to major financial institutions with acceptable credit ratings and monitoring positions with individual counterparties. In addition, we may be required to pledge assets as collateral for our derivatives, whose amounts vary over time based on the market value, notional amount and remaining term of the derivative contract. In the event of a default by a counterparty, we may not receive payments provided for under the terms of our derivative agreements, and may have difficulty obtaining our assets pledged as collateral for our derivatives. The cash and cash equivalents pledged as collateral for our derivative instruments are included in restricted cash on our balance sheets. It is the Company's policy not to offset assets and liabilities associated with open derivative contracts. However, the Chicago Mercantile Exchange (“CME”) rules characterize variation margin transfers as settlement payments, as opposed to adjustments to collateral. As a result, derivative assets and liabilities associated with centrally cleared derivatives for which the CME serves as the central clearing party are presented as if these derivatives had been settled as of the reporting date. |
PLEDGED ASSETS
PLEDGED ASSETS | 12 Months Ended |
Dec. 31, 2020 | |
Financial Instruments Pledged as Collateral [Abstract] | |
Pledged Assets [Text Block] | NOTE 5. PLEDGED ASSETS Assets Pledged to Counterparties The table below summarizes our assets pledged as collateral under our repurchase agreements and derivative agreements by type, including securities pledged related to securities sold but not yet settled, as of December 31, 2020 and 2019. (in thousands) December 31, 2020 December 31, 2019 Repurchase Derivative Repurchase Derivative Assets Pledged to Counterparties Agreements Agreements Total Agreements Agreements Total PT RMBS - fair value $ 3,692,811 $ - $ 3,692,811 $ 3,500,394 $ - $ 3,500,394 Structured RMBS - fair value 27,095 - 27,095 83,960 - 83,960 Accrued interest on pledged securities 9,636 - 9,636 12,367 - 12,367 Restricted cash 58,829 20,534 79,363 65,851 19,034 84,885 Total $ 3,788,371 $ 20,534 $ 3,808,905 $ 3,662,572 $ 19,034 $ 3,681,606 Assets Pledged from Counterparties The table below summarizes our assets pledged to us from counterparties under our repurchase agreements and derivative agreements as of December 31, 2020 and 2019. (in thousands) December 31, 2020 December 31, 2019 Repurchase Derivative Repurchase Derivative Assets Pledged to Orchid Agreements Agreements Total Agreements Agreements Total Cash $ 120 $ 6,083 $ 6,203 $ 1,418 $ - $ 1,418 U.S. Treasury securities - fair value 253 - 253 - - - Total $ 373 $ 6,083 $ 6,456 $ 1,418 $ - $ 1,418 PT RMBS and U.S. Treasury securities received as margin under our repurchase agreements are not recorded in the balance sheets because the counterparty retains ownership of the security. Cash received as margin is recognized in cash and cash equivalents with a corresponding amount recognized as an increase in repurchase agreements or other liabilities in the balance sheets. |
OFFSETTING ASSETS AND LIABILITI
OFFSETTING ASSETS AND LIABILITIES | 12 Months Ended |
Dec. 31, 2020 | |
Offsetting Assets And Liabilities [Abstract] | |
Offsetting Assets and Liabilities [Text Block] | NOTE 6. OFFSETTING ASSETS AND LIABILITIES The Company’s derivative agreements and repurchase agreements are subject to underlying agreements with master netting or similar arrangements, which provide for the right of offset in the event of default or in the event of bankruptcy of either party to the transactions. The Company reports its assets and liabilities subject to these arrangements on a gross basis. The following table presents information regarding those assets and liabilities subject to such arrangements as if the Company had presented them on a net basis as of December 31, 2020 and 2019. (in thousands) Offsetting of Assets Gross Amount Not Net Amount Offset in the Balance Sheet of Assets Financial Gross Amount Gross Amount Presented Instruments Cash of Recognized Offset in the in the Received as Received as Net Assets Balance Sheet Balance Sheet Collateral Collateral Amount December 31, 2020 Interest rate swaps $ 7 $ - $ 7 $ - $ - $ 7 Interest rate swaptions 17,433 - 17,433 - ( 3,563) 13,870 TBA securities 3,559 - 3,559 - ( 2,520) 1,039 $ 20,999 $ - $ 20,999 $ - $ ( 6,083) $ 14,916 (in thousands) Offsetting of Liabilities Gross Amount Not Net Amount Offset in the Balance Sheet of Liabilities Financial Gross Amount Gross Amount Presented Instruments of Recognized Offset in the in the Posted as Cash Posted Net Liabilities Balance Sheet Balance Sheet Collateral Collateral Amount December 31, 2020 Repurchase Agreements $ 3,595,586 $ - $ 3,595,586 $ ( 3,536,757) $ ( 58,829) $ - Interest rate swaps 24,711 - 24,711 - ( 19,761) 4,950 Interest rate swaptions 7,730 - 7,730 - - - TBA securities 786 - 786 - ( 284) 502 $ 3,628,813 $ - $ 3,628,813 $ ( 3,536,757) $ ( 78,874) $ 5,452 December 31, 2019 Repurchase Agreements $ 3,448,106 $ - $ 3,448,106 $ ( 3,382,255) $ ( 65,851) $ - Interest rate swaps 20,146 - 20,146 - ( 17,450) 2,696 TBA securities 512 - 512 - ( 246) 266 $ 3,468,764 $ - $ 3,468,764 $ ( 3,382,255) $ ( 83,547) $ 2,962 The amounts disclosed for collateral received by or posted to the same counterparty up to and not exceeding the net amount of the asset or liability presented in the balance sheets. The fair value of the actual collateral received by or posted to the same counterparty typically exceeds the amounts presented. See Note 5 for a discussion of collateral posted or received against or for repurchase obligations and derivative and other hedging instruments. |
CAPITAL STOCK
CAPITAL STOCK | 12 Months Ended |
Dec. 31, 2020 | |
Capital Stock [Abstract] | |
Capital Stock | NOTE 7. CAPITAL STOCK Common Stock Issuances During 2020 and 2019, the Company completed the following public offerings of shares of its common stock. ($ in thousands, except per share amounts) Weighted Average Price Received Net Type of Offering Period Per Share (1) Shares Proceeds (2) 2020 At the Market Offering Program (3) First Quarter $ 6.23 3,170,727 $ 19,447 At the Market Offering Program (3) Third Quarter 5.15 3,073,326 15,566 At the Market Offering Program (3) Fourth Quarter 5.41 6,775,187 36,037 13,019,240 $ 71,050 2019 At the Market Offering Program (3) First Quarter $ 6.84 1,267,894 $ 8,503 At the Market Offering Program (3) Second Quarter 6.70 4,337,931 28,495 At the Market Offering Program (3) Third Quarter 6.37 1,771,301 11,098 Follow-on Offering (3) Third Quarter 6.35 7,000,000 44,218 14,377,126 $ 92,314 (1) Weighted average price received per share is before deducting the underwriters’ discount, if applicable, and other offering costs. (2) Net proceeds are net of the underwriters’ discount, if applicable, and other offering costs. (3) As of December 31, 2020, the Company had entered into eight equity distribution agreements, seven of which have either been terminated because all shares were sold or were replaced with a subsequent agreement. Stock Repurchase Program On July 29, 2015, the Company’s Board of Directors authorized the repurchase of up to 2,000,000 shares of the Company’s common stock. On February 8, 2018, the Board of Directors approved an increase in the stock repurchase program for up to an additional 4,522,822 shares of the Company's common stock. Coupled with the 783,757 shares remaining from the original 2,0000,000 share authorization, the increased authorization brought the total authorization to 5,306,579 shares, representing 10% of the then outstanding share count. As part of the stock repurchase program, shares may be purchased in open market transactions, block purchases, through privately negotiated transactions, or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Open market repurchases will be made in accordance with Exchange Act Rule 10b-18, which sets certain restrictions on the method, timing, price and volume of open market stock repurchases. The timing, manner, price and amount of any repurchases will be determined by the Company in its discretion and will be subject to economic and market conditions, stock price, applicable legal requirements and other factors. The authorization does not obligate the Company to acquire any particular amount of common stock and the program may be suspended or discontinued at the Company’s discretion without prior notice. From the inception of the stock repurchase program through December 31, 2020, the Company repurchased a total of 5,685,511 shares at an aggregate cost of approximately $ 40.4 million, including commissions and fees, for a weighted average price of $ 7.10 per share. During the year ended December 31, 2020, the Company repurchased a total of 19,891 shares at an aggregate cost of approximately $ 0.1 million, including commissions and fees, for a weighted average price of $ 3.42 per share. During the year ended December 31, 2019, the Company repurchased a total of 469,975 shares at an aggregate cost of approximately $ 3.0 million, including commissions and fees, for a weighted average price of $ 6.43 per share. During the year ended December 31, 2018, the Company repurchased a total of 3,979,402 shares at an aggregate cost of approximately $ 26.4 million, including commissions and fees, for a weighted average price of $ 6.64 per share. The remaining authorization under the repurchase program as of December 31, 2020 is 837,311 shares. Cash Dividends The table below presents the cash dividends declared on the Company’s common stock. (in thousands, except per share amounts) Year Per Share Amount Total 2013 $ 1.395 $ 4,662 2014 2.160 22,643 2015 1.920 38,748 2016 1.680 41,388 2017 1.680 70,717 2018 1.070 55,814 2019 0.960 54,421 2020 0.790 53,570 2021 - YTD (1) 0.130 11,079 Totals $ 11.785 $ 353,042 On January 14, 2021, the Company declared a dividend of $0.065 per share to be paid on February 24, 2021. On February 10, 2021, the Company declared a dividend of $0.065 per share to be paid on March 29, 2021. The dollar amount of the dividend declared in February 2021 is estimated based on the number of shares outstanding at February 26, 2021. The effect of these dividends are included in the table above, but are not reflected in the Company’s financial statements as of December 31, 2020. |
STOCK INCENTIVE PLAN
STOCK INCENTIVE PLAN | 12 Months Ended |
Dec. 31, 2020 | |
Employee Benefits And Share Based Compensation [Abstract] | |
Stock incentive Plan | NOTE 8. STOCK INCENTIVE PLAN In October 2012, the Company’s Board of Directors adopted and Bimini, then the Company’s sole stockholder, approved, the Orchid Island Capital, Inc. 2012 Equity Incentive Plan (the “Incentive Plan”) to recruit and retain employees, directors and other service providers, including employees of the Manager and other affiliates. The Incentive Plan provides for the award of stock options, stock appreciation rights, stock award, performance units, other equity-based awards (and dividend equivalents with respect to awards of performance units and other equity-based awards) and incentive awards. The Incentive Plan is administered by the Compensation Committee of the Company’s Board of Directors except that the Company’s full Board of Directors will administer awards made to directors who are not employees of the Company or its affiliates. The Incentive Plan provides for awards of up to an aggregate of 10% of the issued and outstanding shares of our common stock (on a fully diluted basis) at the time of the awards, subject to a maximum aggregate 4,000,000 shares of the Company’s common stock that may be issued under the Incentive Plan. Stock Awards The Company may in the future issue immediately vested common stock under the Incentive Plan to certain executive officers and employees of its Manager. Although no such awards were granted in fiscal years 2020 or 2019, such awards have previously been issued. Performance Units The Company has issued, and may in the future issue additional performance units under the Incentive Plan to certain executive officers and employees of its Manager. “Performance Units” vest after the end of a defined performance period, based on satisfaction of the performance conditions set forth in the performance unit agreement. When earned, each Performance Unit will be settled by the issuance of one share of the Company’s common stock, at which time the Performance Unit will be cancelled. The Performance Units contain dividend equivalent rights, which entitle the Participants to receive distributions declared by the Company on common stock, but do not include the right to vote the underlying shares of common stock. Performance Units are subject to forfeiture should the participant no longer serve as an executive officer or employee of the Company. Compensation expense for the Performance Units is recognized over the remaining vesting period once it becomes probable that the performance conditions will be achieved. The following table presents information related to Performance Units outstanding during the years ended December 31, 2020 and 2019. ($ in thousands, except per share data) 2020 2019 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Unvested, beginning of period 19,021 $ 7.78 43,672 $ 8.34 Forfeited ( 1,607) 7.45 - - Vested and issued ( 12,860) 7.93 ( 24,651) 8.78 Unvested, end of period 4,554 $ 7.45 19,021 $ 7.78 Compensation expense during period $ 38 $ 115 Unrecognized compensation expense, end of period $ 4 $ 42 Intrinsic value, end of period $ 24 $ 111 Weighted-average remaining vesting term (in years) 0.4 0.8 Deferred Stock Units Non-employee directors began to receive a portion of their compensation in the form of deferred stock unit awards (“DSUs”) pursuant to the Incentive Plan beginning with the awards for the second quarter of 2018. Each DSU represents a right to receive one share of the Company’s common stock. The DSUs are immediately vested and are settled at a future date based on the election of the individual participant. The DSUs contain dividend equivalent rights, which entitle the participant to receive distributions declared by the Company on common stock. These distributions will be made in the form of cash or additional DSUs at the participant’s election. The DSUs do not include the right to vote the underlying shares of common stock. The following table presents information related to the DSUs outstanding during the years ended December 31, 2020 and 2019. ($ in thousands, except per share data) 2020 2019 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Outstanding, beginning of period 43,570 $ 6.56 12,434 $ 7.37 Granted and vested 47,376 4.41 31,136 6.23 Outstanding, end of period 90,946 $ 5.44 43,570 $ 6.56 Compensation expense during period $ 180 $ 180 Intrinsic value, end of period $ 473 $ 255 |
COMMITTMENTS AND CONTINGENCIES
COMMITTMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2020 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments And Contingencies | NOTE 10. COMMITMENTS AND CONTINGENCIES From time to time, the Company may become involved in various claims and legal actions arising in the ordinary course of business. Management is not aware of any reported or unreported contingencies at December 31, 2020. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | NOTE 11. INCOME TAXES The Company will generally not be subject to federal income tax on its REIT taxable income to the extent that it distributes its REIT taxable income to its stockholders and satisfies the ongoing REIT requirements, including meeting certain asset, income and stock ownership tests. A REIT must generally distribute at least 90% of its REIT taxable income to its stockholders, of which 85% generally must be distributed within the taxable year, in order to avoid the imposition of an excise tax. The remaining balance may be distributed up to the end of the following taxable year, provided the REIT elects to treat such amount as a prior year distribution and meets certain other requirements. REIT taxable income (loss) is computed in accordance with the Code, which is different than the Company’s financial statement net income (loss) computed in accordance with GAAP. Book to tax differences primarily relate to the recognition of interest income on RMBS, unrealized gains and losses on RMBS, and the amortization of losses on derivative instruments that are treated as hedges for tax purposes. As of December 31, 2020, we had distributed all of our estimated REIT taxable income through fiscal year 2020. Accordingly, no income tax provision was recorded for 2020, 2019 and 2018. |
EARNINGS PER SHARE
EARNINGS PER SHARE | 12 Months Ended |
Dec. 31, 2020 | |
Earnings Per Share [Abstract] | |
Earnings Per Share (EPS) | NOTE 12. EARNINGS PER SHARE (EPS) The Company had dividend eligible Performance Units and Deferred Stock Units that were outstanding during the years ended December 31, 2020, 2019 and 2018. The basic and diluted per share computations include these unvested Performance Units and Deferred Stock Units if there is income available to common stock, as they have dividend participation rights. The unvested Performance Units and Deferred Stock Units have no contractual obligation to share in losses. Because there is no such obligation, the unvested Performance Units and Deferred Stock Units are not included in the basic and diluted EPS computations when no income is available to common stock even though they are considered participating securities. The table below reconciles the numerator and denominator of EPS for the years ended December 31, 2020, 2019 and 2018. (in thousands, except per-share information) 2020 2019 2018 Basic and diluted EPS per common share: Numerator for basic and diluted EPS per share of common stock: Net income (loss) - Basic and diluted $ 2,128 $ 24,265 $ ( 44,387) Weighted average shares of common stock: Shares of common stock outstanding at the balance sheet date 76,073 63,062 49,132 Unvested dividend eligible share based compensation outstanding at the balance sheet date 96 63 - Effect of weighting ( 8,958) ( 6,797) 3,066 Weighted average shares-basic and diluted 67,211 56,328 52,198 Net income (loss) per common share: Basic and diluted $ 0.03 $ 0.43 $ ( 0.85) Anti-dilutive incentive shares not included in calculation. - - 56 |
FAIR VALUE
FAIR VALUE | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value | NOTE 13. FAIR VALUE The framework for using fair value to measure assets and liabilities defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price). A fair value measure should reflect the assumptions that market participants would use in pricing the asset or liability, including the assumptions about the risk inherent in a particular valuation technique, the effect of a restriction on the sale or use of an asset and the risk of non-performance. Required disclosures include stratification of balance sheet amounts measured at fair value based on inputs the Company uses to derive fair value measurements. These stratifications are: Level 1 valuations, where the valuation is based on quoted market prices for identical assets or liabilities traded in active markets (which include exchanges and over-the-counter markets with sufficient volume), Level 2 valuations, where the valuation is based on quoted market prices for similar instruments traded in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market, and Level 3 valuations, where the valuation is generated from model-based techniques that use significant assumptions not observable in the market, but observable based on Company-specific data. These unobservable assumptions reflect the Company’s own estimates for assumptions that market participants would use in pricing the asset or liability. Valuation techniques typically include option pricing models, discounted cash flow models and similar techniques, but may also include the use of market prices of assets or liabilities that are not directly comparable to the subject asset or liability. The Company's RMBS and TBA securities are Level 2 valuations, and such valuations are determined by the Company based on independent pricing sources and/or third party broker quotes, when available. Because the price estimates may vary, the Company must make certain judgments and assumptions about the appropriate price to use to calculate the fair values. The Company and the independent pricing sources use various valuation techniques to determine the price of the Company’s securities. These techniques include observing the most recent market for like or identical assets (including security coupon, maturity, yield, and prepayment speeds), spread pricing techniques to determine market credit spreads (option adjusted spread, zero volatility spread, spread to the U.S. Treasury curve or spread to a benchmark such as a TBA), and model driven approaches (the discounted cash flow method, Black Scholes and SABR models which rely upon observable market rates such as the term structure of interest rates and volatility). The appropriate spread pricing method used is based on market convention. The pricing source determines the spread of recently observed trade activity or observable markets for assets similar to those being priced. The spread is then adjusted based on variances in certain characteristics between the market observation and the asset being priced. Those characteristics include: type of asset, the expected life of the asset, the stability and predictability of the expected future cash flows of the asset, whether the coupon of the asset is fixed or adjustable, the guarantor of the security if applicable, the coupon, the maturity, the issuer, size of the underlying loans, year in which the underlying loans were originated, loan to value ratio, state in which the underlying loans reside, credit score of the underlying borrowers and other variables if appropriate. The fair value of the security is determined by using the adjusted spread. The Company’s futures contracts are Level 1 valuations, as they are exchange-traded instruments and quoted market prices are readily available. Futures contracts are settled daily. The Company’s interest rate swaps and interest rate swaptions are Level 2 valuations. The fair value of interest rate swaps is determined using a discounted cash flow approach using forward market interest rates and discount rates, which are observable inputs. The fair value of interest rate swaptions is determined using an option pricing model. RMBS (based on the fair value option), derivatives and TBA securities were recorded at fair value on a recurring basis during the years ended December 31, 2020, 2019 and 2018. When determining fair value measurements, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset. When possible, the Company looks to active and observable markets to price identical assets. When identical assets are not traded in active markets, the Company looks to market observable data for similar assets. The following table presents financial assets (liabilities) measured at fair value on a recurring basis as of December 31, 2020 and 2019. Derivative contracts are reported as a net position by contract type, and not based on master netting arrangements. (in thousands) Quoted Prices in Active Significant Markets for Other Significant Identical Observable Unobservable Assets Inputs Inputs (Level 1) (Level 2) (Level 3) December 31, 2020 Mortgage-backed securities $ - $ 3,726,895 $ - Interest rate swaps - ( 24,704) - Interest rate swaptions - 9,703 - TBA securities - 2,773 - December 31, 2019 Mortgage-backed securities $ - $ 3,590,921 $ - Interest rate swaps - ( 20,146) - TBA securities - ( 512) - During the years ended December 31, 2020 and 2019, there were no transfers of financial assets or liabilities between levels 1, 2 or 3. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | NOTE 14. RELATED PARTY TRANSACTIONS Management Agreement The Company is externally managed and advised by the “Manager” pursuant to the terms of a management agreement. The management agreement has been renewed through February 20, 2022 and provides for automatic one-year the terms of the management agreement, the Manager is responsible for administering the business activities and day-to-day operations of the Company. The Manager receives a monthly management fee in the amount of: One-twelfth of 1.5% of the first $250 million of the Company’s month-end equity, as defined in the management agreement, One-twelfth of 1.25% of the Company’s month-end equity that is greater than $250 million and less than or equal to $500 million, and One-twelfth of 1.00% of the Company’s month-end equity that is greater than $500 million. The Company is obligated to reimburse the Manager for any direct expenses incurred on its behalf and to pay the Manager the Company’s pro rata portion of certain overhead costs set forth in the management agreement. Should the Company terminate the management agreement without cause, it will pay the Manager a termination fee equal to three times the average annual management fee, as defined in the management agreement, before or on the last day of the term of the agreement. Total expenses recorded for the management fee and costs incurred were approximately $ 6.8 million, $ 6.9 million and $ 7.8 million for the years ended December 31, 2020, 2019 and 2018, respectively. Other Relationships with Bimini Robert Cauley, our Chief Executive Officer and Chairman of our Board of Directors, also serves as Chief Executive Officer and Chairman of the Board of Directors of Bimini and owns shares of common stock of Bimini. George H. Haas, our Chief Financial Officer, Chief Investment Officer, Secretary and a member of our Board of Directors, also serves as the Chief Financial Officer, Chief Investment Officer and Treasurer of Bimini and owns shares of common stock of Bimini. In addition, as of December 31, 2020, Bimini owned 2,595,357 shares, or 3.4 |
QUARTERLY RESULTS
QUARTERLY RESULTS | 12 Months Ended |
Dec. 31, 2019 | |
Quarterly Financial Information Disclosure [Abstract] | |
Summarized Quarterly Results [Text Block] | NOTE 15. QUARTERLY RESULTS (UNAUDITED) The following is a presentation of the quarterly results of operations for the years ended December 31, 2020 and 2019. (in thousands, except per share information) Quarter Ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 Interest income $ 35,671 $ 27,258 $ 27,223 $ 25,893 Interest expense ( 16,523) ( 4,479) ( 2,043) ( 2,011) Net interest income 19,148 22,779 25,180 23,882 Losses (gains) ( 108,206) 28,749 5,745 ( 4,605) Net portfolio income (loss) ( 89,058) 51,528 30,925 19,277 Expenses: Management fees and overhead expenses 1,724 1,616 1,629 1,826 Other expenses 417 1,140 1,220 972 Total expenses 2,141 2,756 2,849 2,798 Net income (loss) $ ( 91,199) $ 48,772 $ 28,076 $ 16,479 Basic net (loss) income per share $ ( 1.41) $ 0.74 $ 0.42 $ 0.23 Diluted net (loss) income per share $ ( 1.41) $ 0.73 $ 0.42 $ 0.23 Weighted Average Shares Outstanding 64,590 66,310 67,302 70,497 Dividends declared per share $ 0.240 $ 0.165 $ 0.190 $ 0.195 Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 Interest income $ 32,433 $ 36,455 $ 35,907 $ 37,529 Interest expense ( 18,892) ( 22,431) ( 22,321) ( 20,022) Net interest income 13,541 14,024 13,586 17,507 Losses ( 748) ( 7,670) ( 19,431) 3,841 Net portfolio income (loss) 12,793 6,354 ( 5,845) 21,348 Expenses: Management fees and overhead expenses 1,608 1,653 1,791 1,856 Other expenses 588 1,168 841 880 Total expenses 2,196 2,821 2,632 2,736 Net income (loss) $ 10,597 $ 3,533 $ ( 8,477) $ 18,612 Basic and diluted net income (loss) per share $ 0.22 $ 0.07 $ ( 0.14) $ 0.29 Weighted Average Shares Outstanding 48,905 52,601 60,419 63,124 Dividends declared per share $ 0.24 $ 0.24 $ 0.24 $ 0.24 Earnings per share (EPS) in each quarter is computed using the weighted-average number of shares outstanding during that quarter while EPS for the full year is computed using the weighted-average number of shares outstanding during the year. The sum of the four quarters’ EPS may not equal the full year EPS. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 16. SUBSEQUENT EVENTS January 2021 Stock Offering On January 20, 2021, Orchid entered into an underwriting agreement (the “2021 Underwriting Agreement”) with J.P. Morgan Securities LLC (the “Underwriter”), relating to the offer and sale of 7,600,000 shares of the Company’s common stock. The Underwriter purchased the shares of the Company’s common stock from the Company pursuant to the 2021 Underwriting Agreement at $ 5.20 per share. In addition, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,140,000 shares of the Company’s common stock on the same terms and conditions, which the Underwriter exercised in full on January 21, 2021. The closing of the offering of 8,740,000 shares of the Company’s common stock occurred on January 25, 2021, with net proceeds to the Company of approximately $ 45.3 million after deduction of estimated offering expenses payable by the Company. COVID-19 and CARES Act Update The Federal Housing Financing Agency (the “FHFA”) has instructed the GSEs on how they will handle servicer advances for loans that back Agency RMBS that enter into forbearance, which should limit prepayments during the forbearance period that could have resulted otherwise. On January 29, 2021, the CDC issued guidance extending eviction moratoriums for covered persons through March 31, 2021. In addition, on February 9, 2021, the FHFA announced that the foreclosure moratorium begun under the CARES Act for loans backed by Fannie Mae and Freddie Mac and the eviction moratorium for real estate owned by Fannie Mae and Freddie Mac were extended until March 31, 2021. On February 16, 2021, the U.S. Housing and Urban Development Department announced the extension of the FHA eviction and foreclosure moratorium to June 30, 2021. The moratoriums on foreclosures and evictions will likely delay potential defaults on loans that would otherwise be bought out of Agency MBS pools. Depending on the ultimate resolution of the foreclosure or evictions, when and if it occurs, these loans may be removed from the pool into which they were securitized. If this were to occur, it would have the effect of delaying a prepayment on the Company’s securities until such time. As the majority of the Company’s Agency RMBS assets were acquired at a premium to par, this will tend to increase the realized yield on the asset in question. |
BASIS OF PRESENTATION (Policies
BASIS OF PRESENTATION (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | COVID-19 Impact Beginning in mid-March 2020, the global pandemic associated with the novel coronavirus (“COVID-19”) and related economic conditions began to impact our financial position and results of operations. As a result of the economic, health and market turmoil brought about by COVID-19, the Agency RMBS market experienced severe dislocations. This resulted in falling prices of our assets and increased margin calls from our repurchase agreement lenders. Further, as interest rates declined, we faced additional margin calls related to our various hedge positions. In order to maintain sufficient cash and liquidity, reduce risk and satisfy margin calls, we were forced to sell assets at levels significantly below their carrying values and closed several hedge positions. During this period, we sold approximately $ 1.1 billion of Agency RMBS, resulting in losses of approximately $ 31.4 million. Also during this period, we terminated interest rate swap positions with an aggregate notional value of $ 860.0 million and incurred approximately $ 45.0 million in fair value losses on the positions through the date of the respective terminations. The Agency RMBS market largely stabilized after the Federal Reserve announced on March 23, 2020 that it would purchase Agency RMBS and U.S. Treasuries in the amounts needed to support smooth market functioning. As of December 31, 2020, we had timely satisfied all margin calls. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may continue to have adverse effects on the Company’s results of future operations, financial position, and liquidity in fiscal year 2021. In addition, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which has provided billions of dollars of relief to individuals, businesses, state and local governments, and the health care system suffering the impact of the pandemic, including mortgage loan forbearance and modification programs to qualifying borrowers who may have difficulty making their loan payments. As certain time limits imposed in the CARES Act programs began to expire, on December 27, 2020, President Trump signed into law an additional coronavirus aid package as part of the Consolidated Appropriations Act, 2021, providing for extensions of many of the CARES Act policies and programs as well as billions of dollars of additional relief. The Company has evaluated the provisions of the CARES Act and the Consolidated Appropriations Act, 2021 and has determined that it will not have a material effect on the Company’s business, results of operations and financial condition. Basis of Presentation and Use of Estimates The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). |
Use of Estimates | The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates affecting the accompanying financial statements are the fair values of RMBS and derivatives. Management believes the estimates and assumptions underlying the financial statements are reasonable based on the information available as of December 31, 2020; however, uncertainty over the ultimate impact that COVID-19 will have on the global economy generally, and on Orchid’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would beabsent the current and potential impacts of COVID-19. |
Variable Interest Entity [Policy Text Block] | Variable Interest Entities (VIEs) We obtain interests in VIEs through our investments in mortgage-backed securities. Our interests in these VIEs are passive in nature and are not expected to result in us obtaining a controlling financial interest in these VIEs in the future. As a result, we do not consolidate these VIEs and we account for our interest in these VIEs as mortgage-backed securities. See Note 2 for additional information regarding our investments in mortgage-backed securities. Our maximum exposure to loss for these VIEs is the carrying value of the mortgage-backed securities. |
Cash and Cash Equivalents and Restricted Cash | Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents include cash on deposit with financial institutions and highly liquid investments with original maturities of three months or less at the time of purchase. Restricted cash includes cash pledged as collateral for repurchase agreements and other borrowings, and interest rate swaps and other derivative instruments. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. (in thousands) December 31, 2020 December 31, 2019 Cash and cash equivalents $ 220,143 $ 193,770 Restricted cash 79,363 84,885 Total cash, cash equivalents and restricted cash $ 299,506 $ 278,655 The Company maintains cash balances at three banks and excess margin on account with two exchange clearing members. At times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances. The Federal Deposit Insurance Corporation insures eligible accounts up to $250,000 per depositor at each financial institution. Restricted cash balances are uninsured, but are held in separate customer accounts that are segregated from the general funds of the counterparty. The Company limits uninsured balances to only large, well-known banks and exchange clearing members and believes that it is not exposed to any significant credit risk on cash and cash equivalents or restricted cash balances. |
Mortgage-Backed Securities | Mortgage-Backed Securities The Company invests primarily in mortgage pass-through residential mortgage backed certificates issued by Freddie Mac, Fannie Mae or Ginnie Mae (“RMBS”), collateralized mortgage obligations (“CMOs”), interest-only (“IO”) securities and inverse interest-only (“IIO”) securities representing interest in or obligations backed by pools of RMBS. We refer to RMBS and CMOs as PT RMBS. We refer to IO and IIO securities as structured RMBS. The Company has elected to account for its investment in RMBS under the fair value option. Electing the fair value option requires the Company to record changes in fair value in the statement of operations, which, in management’s view, more appropriately reflects the results of our operations for a particular reporting period and is consistent with the underlying economics and how the portfolio is managed. The Company records RMBS transactions on the trade date. Security purchases that have not settled as of the balance sheet date are included in the RMBS balance with an offsetting liability recorded, whereas securities sold that have not settled as of the balance sheet date are removed from the RMBS balance with an offsetting receivable recorded. Fair value is defined as the price that would be received to sell the asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. The fair value measurement assumes that the transaction to sell the asset or transfer the liability either occurs in the principal market for the asset or liability, or in the absence of a principal market, occurs in the most advantageous market for the asset or liability. Estimated fair values for RMBS are based on independent pricing sources and/or third party broker quotes, when available. Income on PT RMBS securities is based on the stated interest rate of the security. Premiums or discounts present at the date of purchase are not amortized. Premium lost and discount accretion resulting from monthly principal repayments are reflected in unrealized gains (losses) on RMBS in the statements of operations. For IO securities, the income is accrued based on the carrying value and the effective yield. The difference between income accrued and the interest received on the security is characterized as a return of investment and serves to reduce the asset’s carrying value. At each reporting date, the effective yield is adjusted prospectively for future reporting periods based on the new estimate of prepayments and the contractual terms of the security. For IIO securities, effective yield and income recognition calculations also take into account the index value applicable to the security. Changes in fair value of RMBS during each reporting period are recorded in earnings and reported as unrealized gains or losses on mortgage-backed securities in the accompanying statements of operations. |
Derivative Financial Instruments | Derivative Financial Instruments The Company uses derivative and other hedging instruments to manage interest rate risk, facilitate asset/liability strategies and manage other exposures, and it may continue to do so in the future. The principal instruments that the Company has used to date are Treasury Note (“T-Note”), Fed Funds and Eurodollar futures contracts, short positions in U.S. Treasury securities, interest rate swaps, options to enter in interest rate swaps (“interest rate swaptions”) and “to-be-announced” (“TBA”) securities transactions, but the Company may enter into other derivative and other hedging instruments in the future. The Company accounts for TBA securities as derivative instruments. Gains and losses associated with TBA securities transactions are reported in gain (loss) on derivative instruments in the accompanying statements of operations. Derivative and other hedging instruments are carried at fair value, and changes in fair value are recorded in earnings for each period. The Company’s derivative financial instruments are not designated as hedge accounting relationships, but rather are used as economic hedges of its portfolio assets and liabilities. Holding derivatives creates exposure to credit risk related to the potential for failure on the part of counterparties and exchanges to honor their commitments. In the event of default by a counterparty, the Company may have difficulty recovering its collateral and may not receive payments provided for under the terms of the agreement. The Company’s derivative agreements require it to post or receive collateral to mitigate such risk. In addition, the Company uses only registered central clearing exchanges and well-established commercial banks as counterparties, monitors positions with individual counterparties and adjusts posted collateral as required. |
Financial Instruments | Financial Instruments The fair value of financial instruments for which it is practicable to estimate that value is disclosed, either in the body of the financial statements or in the accompanying notes. RMBS, Eurodollar, Fed Funds and T-Note futures contracts, interest rate swaps, interest rate swaptions and TBA securities are accounted for at fair value in the balance sheets. The methods and assumptions used to estimate fair value for these instruments are presented in Note 13 of the financial statements. The estimated fair value of cash and cash equivalents, restricted cash, accrued interest receivable, receivable for securities sold, other assets, due to affiliates, repurchase agreements, payable for unsettled securities purchased, accrued interest payable and other liabilities generally approximates their carrying values as of December 31, 2020 and December 31, 2019 due to the short-term nature of these financial instruments. |
Repurchase Agreements | Repurchase Agreements The Company finances the acquisition of the majority of its RMBS through the use of repurchase agreements under master repurchase agreements. Repurchase agreements are accounted for as collateralized financing transactions, which are carried at their contractual amounts, including accrued interest, as specified in the respective agreements. |
Management Fees | Manager Compensation The Company is externally managed by Bimini Advisors, LLC (the “Manager” or “Bimini Advisors”), a Maryland limited liability company and wholly-owned subsidiary of Bimini. The Company’s management agreement with the Manager provides for payment to the Manager of a management fee and reimbursement of certain operating expenses, which are accrued and expensed during the period for which they are earned or incurred. Refer to Note 14 for the terms of the management agreement. |
Earnings Per Share | Earnings Per Share Basic earnings per share (“EPS”) is calculated as net income or loss attributable to common stockholders divided by the weighted average number of shares of common stock outstanding or subscribed during the period. Diluted EPS is calculated using the treasury stock or two-class method, as applicable, for common stock equivalents, if any. However, the common stock equivalents are not included in computing diluted EPS if the result is anti-dilutive. |
Income Taxes | Income Taxes Orchid has qualified and elected to be taxed as a REIT under the Code. REITs are generally not subject to federal income tax on their REIT taxable income provided that they distribute to their stockholders at least 90% of their REIT taxable income on an annual basis. In addition, a REIT must meet other provisions of the Code to retain its tax status. Orchid assesses the likelihood, based on their technical merit, that uncertain tax positions will be sustained upon examination based on the facts, circumstances and information available at the end of each period. All of Orchid’s tax positions are categorized as highly certain. There is no accrual for any tax, interest or penalties related to Orchid’s tax position assessment. The measurement of uncertain tax positions is adjusted when new information is available, or when an event occurs that requires a change. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements On January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires credit losses on most financial assets measured at amortized cost and certain other instruments to be measured using an expected credit loss model (referred to as the current expected credit loss model). The Company’s adoption of this ASU did not have a material effect on its financial statements as its financial assets were already measured at fair value through earnings. In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 provides optional expedients and exceptions to GAAP requirements for modifications on debt instruments, leases, derivatives, and other contracts, related to the expected market transition from the London Interbank Offered Rate (“LIBOR”), and certain other floating rate benchmark indices, or collectively, IBORs, to alternative reference rates. ASU 2020-04 generally considers contract modifications related to reference rate reform to be an event that does not require contract remeasurement at the modification date nor a reassessment of a previous accounting determination. The guidance in ASU 2020-04 is optional and may be elected over time, through December 31, 2022, as reference rate reform activities occur. The Company does not believe the adoption of this ASU will have a material impact on its financial statements. In January 2021, the FASB issued ASU 2021-01 “Reference Rate Reform (Topic 848). ASU 2021-01 expands the scope of ASC 848 to include all affected derivatives and give market participants the ability to apply certain aspects of the contract modification and hedge accounting expedients to derivative contracts affected by the discounting transition. In addition, ASU 2021-01 adds implementation guidance to permit a company to apply certain optional expedients to modifications of interest rate indexes used for margining, discounting or contract price alignment of certain derivatives as a result of reference rate reform initiatives and extends optional expedients to account for a derivative contract modified as a continuation of the existing contract and to continue hedge accounting when certain critical terms of a hedging relationship change to modifications made as part of the discounting transition. The guidance in ASU 2021-01 is effective immediately and available generally through December 31, 2022, as reference rate reform activities occur. The Company does not believe the adoption of this ASU will have a material impact on its financial statements. |
CASH AND CASH EQUIVALENTS AND R
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Schedule of reconciliation of cash, cash equivalents and restricted cash | The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. (in thousands) December 31, 2020 December 31, 2019 Cash and cash equivalents $ 220,143 $ 193,770 Restricted cash 79,363 84,885 Total cash, cash equivalents and restricted cash $ 299,506 $ 278,655 |
MORTGAGE-BACKED SECURITIES (Tab
MORTGAGE-BACKED SECURITIES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Residential Mortgage Backed Securities [Member] | |
Mortgage Backed Securities [Line Items] | |
Schedule of RMBS portfolio | The following table presents the Company’s RMBS portfolio as of December 31, 2020 and December 31, 2019: (in thousands) December 31, 2020 December 31, 2019 Pass-Through RMBS Certificates: Adjustable-rate Mortgages $ - $ 1,014 Fixed-rate Mortgages 3,560,746 3,206,013 Fixed-rate CMOs 137,453 299,205 Total Pass-Through Certificates 3,698,199 3,506,232 Structured RMBS Certificates: Interest-Only Securities 28,696 60,986 Inverse Interest-Only Securities - 23,703 Total Structured RMBS Certificates 28,696 84,689 Total $ 3,726,895 $ 3,590,921 |
REPURCHASE AGREEMENTS AND OTH_2
REPURCHASE AGREEMENTS AND OTHER BORROWINGS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of Repurchase Agreements [Abstract] | |
Schedule of repurchase agreements and remaining maturities | As of December 31, 2020 and 2019, the Company’s repurchase agreements had remaining maturities as summarized below: ($ in thousands) OVERNIGHT BETWEEN 2 BETWEEN 31 GREATER (1 DAY OR AND AND THAN LESS) 30 DAYS 90 DAYS 90 DAYS TOTAL December 31, 2020 Fair market value of securities pledged, including accrued interest receivable $ - $ 2,112,969 $ 1,560,798 $ 55,776 $ 3,729,543 Repurchase agreement liabilities associated with these securities $ - $ 2,047,897 $ 1,494,500 $ 53,189 $ 3,595,586 Net weighted average borrowing rate - 0.23% 0.22% 0.30% 0.23% December 31, 2019 Fair market value of securities pledged, including accrued interest receivable $ - $ 2,470,263 $ 1,005,517 $ 120,941 $ 3,596,721 Repurchase agreement liabilities associated with these securities $ - $ 2,361,378 $ 964,368 $ 122,360 $ 3,448,106 Net weighted average borrowing rate - 2.04% 1.94% 2.60% 2.03% |
DERIVATIVE FINANCIAL INSTRUME_2
DERIVATIVE FINANCIAL INSTRUMENTS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Derivative Financial Instruments [Abstract] | |
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] | The table below summarizes fair value information about our derivative and other hedging instruments assets and liabilities as of December 31, 2020 and 2019. (in thousands) Derivative and Other Hedging Instruments Balance Sheet Location December 31, 2020 December 31, 2019 Assets Interest rate swaps Derivative assets, at fair value $ 7 $ - Payer swaptions (long positions) Derivative assets, at fair value 17,433 - TBA securities Derivative assets, at fair value 3,559 - Total derivative assets, at fair value $ 20,999 $ - Liabilities Interest rate swaps Derivative liabilities, at fair value $ 24,711 $ 20,146 Payer swaptions (short positions) Derivative liabilities, at fair value 7,730 - TBA securities Derivative liabilities, at fair value 786 512 Total derivative liabilities, at fair value $ 33,227 $ 20,658 Margin Balances Posted to (from) Counterparties Futures contracts Restricted cash $ 489 $ 1,338 TBA securities Restricted cash 284 246 TBA securities Other liabilities ( 2,520) - Interest rate swaption contracts Other liabilities ( 3,563) - Interest rate swap contracts Restricted cash 19,761 17,450 Total margin balances on derivative contracts $ 14,451 $ 19,034 |
Schedule of Eurodollar and T-Note futures positions | Eurodollar, Fed Funds and T-Note futures are cash settled futures contracts on an interest rate, with gains and losses credited or charged to the Company’s cash accounts on a daily basis. A minimum balance, or “margin”, is required to be maintained in the account on a daily basis. The tables below present information related to the Company’s Eurodollar and T-Note futures positions at December 31, 2020 and 2019. ($ in thousands) December 31, 2020 Average Weighted Weighted Contract Average Average Notional Entry Effective Open Expiration Year Amount Rate Rate Equity (1) Eurodollar Futures Contracts (Short Positions) 2021 $ 50,000 1.03% 0.18% $ ( 424) U.S. Treasury Note Futures Contracts (Short Position) (2) March 2021 5-year T-Note futures (Mar 2021 - Mar 2026 Hedge Period) $ 69,000 0.72% 0.67% $ ( 186) ($ in thousands) December 31, 2019 Average Weighted Weighted Contract Average Average Notional Entry Effective Open Expiration Year Amount Rate Rate Equity (1) Eurodollar Futures Contracts (Short Positions) 2020 $ 500,000 2.97% 1.67% $ ( 6,505) U.S. Treasury Note Futures Contracts (Short Position) (2) March 2020 5 year T-Note futures (Mar 2020 - Mar 2025 Hedge Period) $ 69,000 1.96% 2.06% $ 302 (1) Open equity represents the cumulative gains (losses) recorded on open futures positions from inception. (2) T-Note futures contracts were valued at a price of $ 126.16 at December 31, 2020 and $ 118.61 at December 31, 2019. The contract values of the short positions were $ 87.1 million and $ 81.8 million at December 31, 2020 and December 31, 2019, respectively. |
Schedule of Interest Rate Swap Agreements [Table Text Block] | 3 to ≤ 5 years $ 620,000 1.29% 0.22% $ ( 23,760) 3.6 Expiration > 5 years $ 200,000 0.67% 0.23% $ ( 944) 6.4 $ 820,000 1.14% 0.23% $ ( 24,704) 4.3 December 31, 2019 Expiration > 1 to ≤ 3 years $ 360,000 2.05% 1.90% $ ( 3,680) 2.3 Expiration > 3 to ≤ 5 years 910,000 2.03% 1.93% ( 16,466) 4.4 $ 1,270,000 2.03% 1.92% $ ( 20,146) 3.8" id="sjs-B6">Under our interest rate swap agreements, we typically pay a fixed rate and receive a floating rate based on LIBOR ("payer swaps"). The floating rate we receive under our swap agreements has the effect of offsetting the repricing characteristics of our repurchase agreements and cash flows on such liabilities. We are typically required to post collateral on our interest rate swap agreements. The table below presents information related to the Company’s interest rate swap positions at December 31, 2020 and 2019. ($ in thousands) Average Net Fixed Average Estimated Average Notional Pay Receive Fair Maturity Amount Rate Rate Value (Years) December 31, 2020 Expiration > 3 to ≤ 5 years $ 620,000 1.29% 0.22% $ ( 23,760) 3.6 Expiration > 5 years $ 200,000 0.67% 0.23% $ ( 944) 6.4 $ 820,000 1.14% 0.23% $ ( 24,704) 4.3 December 31, 2019 Expiration > 1 to ≤ 3 years $ 360,000 2.05% 1.90% $ ( 3,680) 2.3 Expiration > 3 to ≤ 5 years 910,000 2.03% 1.93% ( 16,466) 4.4 $ 1,270,000 2.03% 1.92% $ ( 20,146) 3.8 |
Schedule Of Interest Rate Swaption Agreements [Table Text Block] | The table below presents information related to the Company’s interest rate swaption positions at December 31, 2020. There were no open swaption positions at December 31, 2019. ($ in thousands) Option Underlying Swap Weighted Average Weighted Average Average Adjustable Average Fair Months to Notional Fixed Rate Term Expiration Cost Value Expiration Amount Rate (LIBOR) (Years) December 31, 2020 Payer Swaptions (long positions) ≤ 1 year $ 3,450 $ 5 2.5 500,000 0.95% 3 Month 4.0 > 1 year ≤ 2 years 13,410 17,428 17.4 675,000 1.49% 3 Month 12.8 $ 16,860 $ 17,433 11.0 $ 1,175,000 1.26% 3 Month 9.0 Payer Swaptions (short positions) ≤ 1 year $ ( 4,660) $ ( 7,730) 5.4 $ 507,700 1.49% 3 Month 12.8 |
Schedule of To Be Announced Securities [TableTextBlock] | The following table summarizes our contracts to purchase and sell TBA securities as of December 31, 2020 and 2019. ($ in thousands) Notional Net Amount Cost Market Carrying Long (Short) (1) Basis (2) Value (3) Value (4) December 31, 2020 30-Year TBA securities: 2.0% $ 465,000 $ 479,531 $ 483,090 $ 3,559 3.0% ( 328,000) ( 342,896) ( 343,682) ( 786) Total $ 137,000 $ 136,635 $ 139,408 $ 2,773 December 31, 2019 30-Year TBA securities: 4.5% $ ( 300,000) $ ( 315,426) $ ( 315,938) $ ( 512) Total $ ( 300,000) $ ( 315,426) $ ( 315,938) $ ( 512) |
Schedule of the effect of the Company's deriviative financial instruments on the consolidated statement of operations | Gain (Loss) From Derivative and Other Hedging Instruments, Net The table below presents the effect of the Company’s derivative and other hedging instruments on the statements of operations for the years ended December 31, 2020, 2019 and 2018. (in thousands) 2020 2019 2018 Eurodollar futures contracts (short positions) $ ( 8,337) $ ( 13,860) $ 7,170 U.S. Treasury Note futures contracts (short position) ( 4,707) ( 5,175) 5,507 Fed Funds futures contracts (short positions) - 177 - Interest rate swaps ( 66,212) ( 26,582) 8,609 Receiver swaptions - - 105 Payer swaptions (long positions) 98 ( 1,379) ( 1,607) Payer swaptions (short positions) ( 3,070) - - TBA securities (short positions) ( 6,719) ( 6,264) 4,327 TBA securities (long positions) 9,950 1,907 200 U.S. Treasury securities (short positions) ( 95) - - Total $ ( 79,092) $ ( 51,176) $ 24,311 |
PLEDGED ASSETS (Tables)
PLEDGED ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Financial Instruments Pledged as Collateral [Abstract] | |
Schedule of assets pledged as collateral under our repurchase agreements, prime brokerage clearing accounts, derivative agreements and insurance capital by type, including securities pledged related to securities sold but not yet settled | Assets Pledged to Counterparties The table below summarizes our assets pledged as collateral under our repurchase agreements and derivative agreements by type, including securities pledged related to securities sold but not yet settled, as of December 31, 2020 and 2019. (in thousands) December 31, 2020 December 31, 2019 Repurchase Derivative Repurchase Derivative Assets Pledged to Counterparties Agreements Agreements Total Agreements Agreements Total PT RMBS - fair value $ 3,692,811 $ - $ 3,692,811 $ 3,500,394 $ - $ 3,500,394 Structured RMBS - fair value 27,095 - 27,095 83,960 - 83,960 Accrued interest on pledged securities 9,636 - 9,636 12,367 - 12,367 Restricted cash 58,829 20,534 79,363 65,851 19,034 84,885 Total $ 3,788,371 $ 20,534 $ 3,808,905 $ 3,662,572 $ 19,034 $ 3,681,606 |
Schedule of assets pledged to us from counterparties under our repurchase agreements. | Assets Pledged from Counterparties The table below summarizes our assets pledged to us from counterparties under our repurchase agreements and derivative agreements as of December 31, 2020 and 2019. (in thousands) December 31, 2020 December 31, 2019 Repurchase Derivative Repurchase Derivative Assets Pledged to Orchid Agreements Agreements Total Agreements Agreements Total Cash $ 120 $ 6,083 $ 6,203 $ 1,418 $ - $ 1,418 U.S. Treasury securities - fair value 253 - 253 - - - Total $ 373 $ 6,083 $ 6,456 $ 1,418 $ - $ 1,418 |
OFFSETTING ASSETS AND LIABILI_2
OFFSETTING ASSETS AND LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Offsetting Assets And Liabilities [Abstract] | |
Offsetting of Assets [Table Text Block] | The following table presents information regarding those assets and liabilities subject to such arrangements as if the Company had presented them on a net basis as of December 31, 2020 and 2019. (in thousands) Offsetting of Assets Gross Amount Not Net Amount Offset in the Balance Sheet of Assets Financial Gross Amount Gross Amount Presented Instruments Cash of Recognized Offset in the in the Received as Received as Net Assets Balance Sheet Balance Sheet Collateral Collateral Amount December 31, 2020 Interest rate swaps $ 7 $ - $ 7 $ - $ - $ 7 Interest rate swaptions 17,433 - 17,433 - ( 3,563) 13,870 TBA securities 3,559 - 3,559 - ( 2,520) 1,039 $ 20,999 $ - $ 20,999 $ - $ ( 6,083) $ 14,916 |
Offsetting of Liabilties [Table Text Block] | (in thousands) Offsetting of Liabilities Gross Amount Not Net Amount Offset in the Balance Sheet of Liabilities Financial Gross Amount Gross Amount Presented Instruments of Recognized Offset in the in the Posted as Cash Posted Net Liabilities Balance Sheet Balance Sheet Collateral Collateral Amount December 31, 2020 Repurchase Agreements $ 3,595,586 $ - $ 3,595,586 $ ( 3,536,757) $ ( 58,829) $ - Interest rate swaps 24,711 - 24,711 - ( 19,761) 4,950 Interest rate swaptions 7,730 - 7,730 - - - TBA securities 786 - 786 - ( 284) 502 $ 3,628,813 $ - $ 3,628,813 $ ( 3,536,757) $ ( 78,874) $ 5,452 December 31, 2019 Repurchase Agreements $ 3,448,106 $ - $ 3,448,106 $ ( 3,382,255) $ ( 65,851) $ - Interest rate swaps 20,146 - 20,146 - ( 17,450) 2,696 TBA securities 512 - 512 - ( 246) 266 $ 3,468,764 $ - $ 3,468,764 $ ( 3,382,255) $ ( 83,547) $ 2,962 |
CAPITAL STOCK (Tables)
CAPITAL STOCK (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Capital Stock [Abstract] | |
Schedule of completed public offerings of shares of common stock | Common Stock Issuances During 2020 and 2019, the Company completed the following public offerings of shares of its common stock. ($ in thousands, except per share amounts) Weighted Average Price Received Net Type of Offering Period Per Share (1) Shares Proceeds (2) 2020 At the Market Offering Program (3) First Quarter $ 6.23 3,170,727 $ 19,447 At the Market Offering Program (3) Third Quarter 5.15 3,073,326 15,566 At the Market Offering Program (3) Fourth Quarter 5.41 6,775,187 36,037 13,019,240 $ 71,050 2019 At the Market Offering Program (3) First Quarter $ 6.84 1,267,894 $ 8,503 At the Market Offering Program (3) Second Quarter 6.70 4,337,931 28,495 At the Market Offering Program (3) Third Quarter 6.37 1,771,301 11,098 Follow-on Offering (3) Third Quarter 6.35 7,000,000 44,218 14,377,126 $ 92,314 (1) Weighted average price received per share is before deducting the underwriters’ discount, if applicable, and other offering costs. (2) Net proceeds are net of the underwriters’ discount, if applicable, and other offering costs. (3) As of December 31, 2020, the Company had entered into eight equity distribution agreements, seven of which have either been terminated because all shares were sold or were replaced with a subsequent agreement. |
Schedul of cash dividends declared on the Company's common stock | Cash Dividends The table below presents the cash dividends declared on the Company’s common stock. (in thousands, except per share amounts) Year Per Share Amount Total 2013 $ 1.395 $ 4,662 2014 2.160 22,643 2015 1.920 38,748 2016 1.680 41,388 2017 1.680 70,717 2018 1.070 55,814 2019 0.960 54,421 2020 0.790 53,570 2021 - YTD (1) 0.130 11,079 Totals $ 11.785 $ 353,042 On January 14, 2021, the Company declared a dividend of $0.065 per share to be paid on February 24, 2021. On February 10, 2021, the Company declared a dividend of $0.065 per share to be paid on March 29, 2021. The dollar amount of the dividend declared in February 2021 is estimated based on the number of shares outstanding at February 26, 2021. The effect of these dividends are included in the table above, but are not reflected in the Company’s financial statements as of December 31, 2020. |
STOCK INCENTIVE PLANS (Tables)
STOCK INCENTIVE PLANS (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Employee Benefits And Share Based Compensation [Abstract] | |
Schedule of Performance Units outstanding | ($ in thousands, except per share data) 2020 2019 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Unvested, beginning of period 19,021 $ 7.78 43,672 $ 8.34 Forfeited ( 1,607) 7.45 - - Vested and issued ( 12,860) 7.93 ( 24,651) 8.78 Unvested, end of period 4,554 $ 7.45 19,021 $ 7.78 Compensation expense during period $ 38 $ 115 Unrecognized compensation expense, end of period $ 4 $ 42 Intrinsic value, end of period $ 24 $ 111 Weighted-average remaining vesting term (in years) 0.4 0.8 |
Schedule of Fully Vested Deferred Stock Units | The following table presents information related to the DSUs outstanding during the years ended December 31, 2020 and 2019. ($ in thousands, except per share data) 2020 2019 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Outstanding, beginning of period 43,570 $ 6.56 12,434 $ 7.37 Granted and vested 47,376 4.41 31,136 6.23 Outstanding, end of period 90,946 $ 5.44 43,570 $ 6.56 Compensation expense during period $ 180 $ 180 Intrinsic value, end of period $ 473 $ 255 |
EARNINGS PER SHARE (Tables)
EARNINGS PER SHARE (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Earnings Per Share [Abstract] | |
Schedule of reconciling the numerator and denominator of EPS | The table below reconciles the numerator and denominator of EPS for the years ended December 31, 2020, 2019 and 2018. (in thousands, except per-share information) 2020 2019 2018 Basic and diluted EPS per common share: Numerator for basic and diluted EPS per share of common stock: Net income (loss) - Basic and diluted $ 2,128 $ 24,265 $ ( 44,387) Weighted average shares of common stock: Shares of common stock outstanding at the balance sheet date 76,073 63,062 49,132 Unvested dividend eligible share based compensation outstanding at the balance sheet date 96 63 - Effect of weighting ( 8,958) ( 6,797) 3,066 Weighted average shares-basic and diluted 67,211 56,328 52,198 Net income (loss) per common share: Basic and diluted $ 0.03 $ 0.43 $ ( 0.85) Anti-dilutive incentive shares not included in calculation. - - 56 |
FAIR VALUE (Tables)
FAIR VALUE (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Schedule of financial assets (liabilities) measured at fair value on a recurring basis | The following table presents financial assets (liabilities) measured at fair value on a recurring basis as of December 31, 2020 and 2019. Derivative contracts are reported as a net position by contract type, and not based on master netting arrangements. (in thousands) Quoted Prices in Active Significant Markets for Other Significant Identical Observable Unobservable Assets Inputs Inputs (Level 1) (Level 2) (Level 3) December 31, 2020 Mortgage-backed securities $ - $ 3,726,895 $ - Interest rate swaps - ( 24,704) - Interest rate swaptions - 9,703 - TBA securities - 2,773 - December 31, 2019 Mortgage-backed securities $ - $ 3,590,921 $ - Interest rate swaps - ( 20,146) - TBA securities - ( 512) - |
QUARTERLY RESULTS - (Tables)
QUARTERLY RESULTS - (Tables) | 12 Months Ended |
Dec. 31, 2019 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Quarterly Financia lInformation [TableTextBlock] | NOTE 15. QUARTERLY RESULTS (UNAUDITED) The following is a presentation of the quarterly results of operations for the years ended December 31, 2020 and 2019. (in thousands, except per share information) Quarter Ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 Interest income $ 35,671 $ 27,258 $ 27,223 $ 25,893 Interest expense ( 16,523) ( 4,479) ( 2,043) ( 2,011) Net interest income 19,148 22,779 25,180 23,882 Losses (gains) ( 108,206) 28,749 5,745 ( 4,605) Net portfolio income (loss) ( 89,058) 51,528 30,925 19,277 Expenses: Management fees and overhead expenses 1,724 1,616 1,629 1,826 Other expenses 417 1,140 1,220 972 Total expenses 2,141 2,756 2,849 2,798 Net income (loss) $ ( 91,199) $ 48,772 $ 28,076 $ 16,479 Basic net (loss) income per share $ ( 1.41) $ 0.74 $ 0.42 $ 0.23 Diluted net (loss) income per share $ ( 1.41) $ 0.73 $ 0.42 $ 0.23 Weighted Average Shares Outstanding 64,590 66,310 67,302 70,497 Dividends declared per share $ 0.240 $ 0.165 $ 0.190 $ 0.195 Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 Interest income $ 32,433 $ 36,455 $ 35,907 $ 37,529 Interest expense ( 18,892) ( 22,431) ( 22,321) ( 20,022) Net interest income 13,541 14,024 13,586 17,507 Losses ( 748) ( 7,670) ( 19,431) 3,841 Net portfolio income (loss) 12,793 6,354 ( 5,845) 21,348 Expenses: Management fees and overhead expenses 1,608 1,653 1,791 1,856 Other expenses 588 1,168 841 880 Total expenses 2,196 2,821 2,632 2,736 Net income (loss) $ 10,597 $ 3,533 $ ( 8,477) $ 18,612 Basic and diluted net income (loss) per share $ 0.22 $ 0.07 $ ( 0.14) $ 0.29 Weighted Average Shares Outstanding 48,905 52,601 60,419 63,124 Dividends declared per share $ 0.24 $ 0.24 $ 0.24 $ 0.24 |
ORGANIZATION AND SIGNIFICANT _2
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Capital Raising Activities (Narrative) (Details) - USD ($) | Jan. 25, 2021 | Aug. 02, 2019 | Feb. 26, 2021 | Dec. 31, 2020 | Aug. 03, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Aug. 11, 2019 |
Subsidiary, Sale of Stock [Line Items] | |||||||||
Proceeds From Issuance Of Common Stock, net of issuance costs | $ 71,050,000 | $ 92,314,000 | $ 0 | ||||||
Stock Issued During Period, Value, New Issues | $ 71,050,000 | $ 92,314,000 | |||||||
Total shares issued under distribution agreement | 13,019,240 | 14,377,126 | |||||||
At the Market Offering Program [Member] | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Proceeds From Issuance Of Common Stock, net of issuance costs | $ 51,600,000 | $ 19,400,000 | $ 123,100,000 | ||||||
Stock Issued During Period, Value, New Issues | $ 1,600,000 | $ 52,500,000 | $ 19,800,000 | $ 125,000,000 | |||||
Total shares issued under distribution agreement | 308,048 | 9,848,513 | 3,170,727 | 15,123,178 | |||||
At the Market Offering Program [Member] | Maximum [Member] | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Stock Issued During Period, Value, New Issues | $ 150,000,000 | $ 200,000,000 | $ 125,000,000 | ||||||
Follow-on Offering [Member] | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Proceeds From Issuance Of Common Stock, net of issuance costs | $ 45,300,000 | $ 44,200,000 | |||||||
Total shares issued under distribution agreement | 8,740,000 | 7,000,000 | |||||||
Share Price | $ 5.20 | $ 6.3535 | |||||||
Follow-on Offering [Member] | Maximum [Member] | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Total shares issued under distribution agreement | 7,000,000 | ||||||||
Share Price | $ 6.55 |
ORGANIZATION AND SIGNIFICANT _3
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - COVID-19 Impact (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
COVID-19 Impact [Line Items] | |||
Proceeds From Sale Of Mortgage Backed Securities MBS Categorized As Trading | $ 4,200,536 | $ 3,321,206 | $ 3,885,817 |
Marketable Securities, Realized Gain (Loss) | (24,986) | (10,877) | (30,289) |
Gain Loss On Derivative Instruments Held For Trading Purposes Net | (79,092) | (51,176) | 24,311 |
COVID-19 [Member] | |||
COVID-19 Impact [Line Items] | |||
Proceeds From Sale Of Mortgage Backed Securities MBS Categorized As Trading | 1,100,000 | ||
Marketable Securities, Realized Gain (Loss) | (31,400) | ||
Swap [Member] | |||
COVID-19 Impact [Line Items] | |||
Gain Loss On Derivative Instruments Held For Trading Purposes Net | (66,212) | $ (26,582) | $ 8,609 |
Swap [Member] | COVID-19 [Member] | |||
COVID-19 Impact [Line Items] | |||
Terminated Swap Positions Notional | 860,000 | ||
Gain Loss On Derivative Instruments Held For Trading Purposes Net | $ (45,000) |
ORGANIZATION AND SIGINIFICANT A
ORGANIZATION AND SIGINIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 220,143 | $ 193,770 | ||
Restricted cash | 79,363 | 84,885 | ||
Total cash, cash equivalents and restricted cash | $ 299,506 | $ 278,655 | $ 126,263 | $ 246,712 |
MORTGAGE-BACKED SECURITIES - RM
MORTGAGE-BACKED SECURITIES - RMBS portfolio (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | $ 3,726,895 | $ 3,590,921 |
Total Pass Through Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | 3,698,199 | 3,506,232 |
Total Strucutured RMBS Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | 28,696 | 84,689 |
Adjustable-rate Mortgages [Member] | Total Pass Through Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | 0 | 1,014 |
Fixed-rate Mortgages [Member] | Total Pass Through Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | 3,560,746 | 3,206,013 |
Collateralized Mortgage Obligations [Member] | Total Pass Through Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | 137,453 | 299,205 |
Interest-Only Securities [Member] | Total Strucutured RMBS Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | 28,696 | 60,986 |
Inverse Interest-Only Securities [Member] | Total Strucutured RMBS Certificates [Member] | ||
Schedule of Trading Securities and Other Trading Assets [Line Items] | ||
Fair Value | $ 0 | $ 23,703 |
REPURCHASE AGREEMENTS AND REVER
REPURCHASE AGREEMENTS AND REVERSE REPURCHASE AGREEMENTS (Narrative) (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Assets Sold under Agreements to Repurchase [Line Items] | ||
Restricted Cash And Cash Equivalents At Carrying Value | $ 79,363 | $ 84,885 |
Repurchase Agreement [Member] | ||
Assets Sold under Agreements to Repurchase [Line Items] | ||
Aggregate amount at risk with all counterparties | 176,300 | |
Restricted Cash And Cash Equivalents At Carrying Value | $ 58,829 | $ 65,851 |
REPURCHASE AGREEMENTS AND REV_2
REPURCHASE AGREEMENTS AND REVERSE REPURCHASE AGREEMENTS - Remaining Maturities (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Assets Sold under Agreements to Repurchase [Line Items] | ||
Fair Value of securities pledged, including accrued interest receivable | $ 3,729,543 | $ 3,596,721 |
Repurchase agreement liabilities associated with these liabilities | $ 3,595,586 | $ 3,448,106 |
Net weighted average borrowing rate | 0.23% | 2.03% |
Overnight (1 Day or Less) [Member] | ||
Assets Sold under Agreements to Repurchase [Line Items] | ||
Fair Value of securities pledged, including accrued interest receivable | $ 0 | $ 0 |
Repurchase agreement liabilities associated with these liabilities | $ 0 | $ 0 |
Net weighted average borrowing rate | 0.00% | 0.00% |
Between 2 and 30 Days [Member] | ||
Assets Sold under Agreements to Repurchase [Line Items] | ||
Fair Value of securities pledged, including accrued interest receivable | $ 2,112,969 | $ 2,470,263 |
Repurchase agreement liabilities associated with these liabilities | $ 2,047,897 | $ 2,361,378 |
Net weighted average borrowing rate | 0.23% | 2.04% |
Between 31 and 90 Days [Member] | ||
Assets Sold under Agreements to Repurchase [Line Items] | ||
Fair Value of securities pledged, including accrued interest receivable | $ 1,560,798 | $ 1,005,517 |
Repurchase agreement liabilities associated with these liabilities | $ 1,494,500 | $ 964,368 |
Net weighted average borrowing rate | 0.22% | 1.94% |
Greater Than 90 days [Member] | ||
Assets Sold under Agreements to Repurchase [Line Items] | ||
Fair Value of securities pledged, including accrued interest receivable | $ 55,776 | $ 120,941 |
Repurchase agreement liabilities associated with these liabilities | $ 53,189 | $ 122,360 |
Net weighted average borrowing rate | 0.30% | 2.60% |
DERIVATIVE FINANCIAL INSTRUME_3
DERIVATIVE FINANCIAL INSTRUMENTS - Schedule of Derivative Assets and Liabilties (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Derivative [Line Items] | ||
Assets, at Fair Value | $ 20,999 | $ 0 |
Liabilities, at Fair Value | 33,227 | 20,658 |
Restricted cash | 79,363 | 84,885 |
Other Liabilities | 7,188 | 1,041 |
Not Designated as Hedging Instrument, Economic Hedge [Member] | ||
Derivative [Line Items] | ||
Assets, at Fair Value | 20,999 | 0 |
Liabilities, at Fair Value | 33,227 | 20,658 |
Restricted cash | 14,451 | 19,034 |
Interest Rate Swap [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | ||
Derivative [Line Items] | ||
Assets, at Fair Value | 7 | 0 |
Liabilities, at Fair Value | 24,711 | 20,146 |
Restricted cash | 19,761 | 17,450 |
TBA Contracts [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | ||
Derivative [Line Items] | ||
Assets, at Fair Value | 3,559 | 0 |
Liabilities, at Fair Value | 786 | 512 |
Restricted cash | 284 | 246 |
Other Liabilities | 2,520 | 0 |
Eurodollar Future Margin [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | ||
Derivative [Line Items] | ||
Restricted cash | 489 | 1,338 |
Payer Swaption [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | ||
Derivative [Line Items] | ||
Other Liabilities | 3,563 | 0 |
Payer Swaption [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | Short [Member] | ||
Derivative [Line Items] | ||
Liabilities, at Fair Value | 7,730 | 0 |
Payer Swaption [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member] | Long [Member] | ||
Derivative [Line Items] | ||
Assets, at Fair Value | $ 17,433 | $ 0 |
DERIVATIVE FINANCIAL INSTRUME_4
DERIVATIVE FINANCIAL INSTRUMENTS - Eurodollar and T-Note futures positions (Details) - Short [Member] - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
Year 2020 Expiration [Member] | Eurodollar Future [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 500,000,000 | |
Derivative Entry Rate | 2.97% | |
Locked-In LIBOR Rate | 1.67% | |
Open Equity | $ (6,505,000) | |
Year 2020 Expiration [Member] | Treasury Note Futures [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 69,000,000 | |
Derivative Entry Rate | 1.96% | |
Locked-In LIBOR Rate | 2.06% | |
Open Equity | $ 302,000 | |
Dollar Price | 118.61 | |
Contract Value | $ 81,800,000 | |
Year 2021 Expiration [Member] | Eurodollar Future [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 50,000,000 | |
Derivative Entry Rate | 1.03% | |
Locked-In LIBOR Rate | 0.18% | |
Open Equity | $ (424,000) | |
Year 2021 Expiration [Member] | Treasury Note Futures [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 69,000,000 | |
Derivative Entry Rate | 0.72% | |
Locked-In LIBOR Rate | 0.67% | |
Open Equity | $ (186,000) | |
Dollar Price | 126.16 | |
Contract Value | $ 87,100,000 |
DERIVATIVE FINANCIAL INSTRUME_5
DERIVATIVE FINANCIAL INSTRUMENTS - Interest rate swap positions (Details) - Swap [Member] - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 820,000 | $ 1,270,000 |
Average Fixed Pay Rate | 1.14% | 2.05% |
Average Receive Rate | 0.23% | 1.90% |
Net Estimated Fair Value | $ (24,704) | $ (20,146) |
Average Maturity | 4 years 3 months 18 days | 3 years 9 months 18 days |
1-3 Years | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 360,000 | |
Average Fixed Pay Rate | 2.03% | |
Average Receive Rate | 1.93% | |
Net Estimated Fair Value | $ (3,680) | |
Average Maturity | 2 years 3 months 18 days | |
3-5 Years | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 620,000 | $ 910,000 |
Average Fixed Pay Rate | 1.29% | 2.03% |
Average Receive Rate | 0.22% | 1.92% |
Net Estimated Fair Value | $ (23,760) | $ (16,466) |
Average Maturity | 3 years 7 months 6 days | 4 years 4 months 24 days |
More Than Five Years [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 200,000 | |
Average Fixed Pay Rate | 0.67% | |
Average Receive Rate | 0.23% | |
Net Estimated Fair Value | $ (944) | |
Average Maturity | 6 years 4 months 24 days |
DERIVATIVE FINANCIAL INTSTRUMEN
DERIVATIVE FINANCIAL INTSTRUMENTS - Summary of Outstanding Swaptions (Details) - Payer Swaption [Member] $ in Thousands | 12 Months Ended |
Dec. 31, 2020USD ($) | |
Long [Member] | |
Derivatives, Fair Value [Line Items] | |
Swaption Cost | $ 16,860 |
Net Estimated Fair Value | $ 17,433 |
Derivative Instruments Average Months To Expiration | 11 months |
Notional Amount | $ 1,175,000 |
Derivative Average Fixed Interest Rate | 1.26% |
Derivative Avergage Receive Rate | 3 Month |
Term (Years) | 9 years |
Less Than Or Equal To One Year [Member] | Short [Member] | |
Derivatives, Fair Value [Line Items] | |
Swaption Cost | $ (4,660) |
Net Estimated Fair Value | $ (7,730) |
Derivative Instruments Average Months To Expiration | 5 months 12 days |
Notional Amount | $ 507,700 |
Derivative Average Fixed Interest Rate | 1.49% |
Derivative Avergage Receive Rate | 3 Month |
Term (Years) | 12 years 9 months 18 days |
Less Than Or Equal To One Year [Member] | Long [Member] | |
Derivatives, Fair Value [Line Items] | |
Swaption Cost | $ 3,450 |
Net Estimated Fair Value | $ 5 |
Derivative Instruments Average Months To Expiration | 2 months 15 days |
Notional Amount | $ 500,000 |
Derivative Average Fixed Interest Rate | 0.95% |
Derivative Avergage Receive Rate | 3 Month |
Term (Years) | 4 years |
One Year To Two Years [Member] | Long [Member] | |
Derivatives, Fair Value [Line Items] | |
Swaption Cost | $ 13,410 |
Net Estimated Fair Value | $ 17,428 |
Derivative Instruments Average Months To Expiration | 17 months 12 days |
Notional Amount | $ 675,000 |
Derivative Average Fixed Interest Rate | 1.49% |
Derivative Avergage Receive Rate | 3 Month |
Term (Years) | 12 years 9 months 18 days |
DERIVATIVE FINANCIAL INSTRUME_6
DERIVATIVE FINANCIAL INSTRUMENTS - TBA positions (Details) - 30 Year [Member] - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 137,000 | $ 300,000 |
Cost Basis | 136,635 | (315,426) |
Market Value Of TBA Contract | 139,408 | (315,938) |
Net Estimated Fair Value | 2,773 | (512) |
2.0% [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | 465,000 | |
Cost Basis | 479,531 | |
Market Value Of TBA Contract | 483,090 | |
Net Estimated Fair Value | 3,559 | |
4.5% [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | 300,000 | |
Cost Basis | (315,426) | |
Market Value Of TBA Contract | (315,938) | |
Net Estimated Fair Value | $ (512) | |
3.0% [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | 328,000 | |
Cost Basis | (342,896) | |
Market Value Of TBA Contract | (343,682) | |
Net Estimated Fair Value | $ (786) |
DERIVATIVE FINANCIAL INSTRUME_7
DERIVATIVE FINANCIAL INSTRUMENTS - Effect on the consolidated statements of operations (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | $ (79,092) | $ (51,176) | $ 24,311 |
Eurodollar Future [Member] | Short [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | (8,337) | (13,860) | 5,507 |
Treasury Note Future [Member] | Short [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | (4,707) | (5,175) | 0 |
Swap [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | (66,212) | (26,582) | 8,609 |
Payer Swaption [Member] | Short [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | (3,070) | 0 | 0 |
Payer Swaption [Member] | Long [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | 98 | (1,379) | (1,607) |
TBA Contracts [Member] | Short [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | (6,719) | (6,264) | 4,327 |
TBA Contracts [Member] | Long [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | 9,950 | 1,907 | 200 |
US Treasury Securities [Member] | Short [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | (95) | 0 | 0 |
Fed Funds Future [Member] | Short [Member] | |||
Derivatives, Fair Value [Line Items] | |||
(Losses) gains on derivative instruments | $ 0 | $ 177 | $ 0 |
PLEDGED ASSETS - Assets Pledged
PLEDGED ASSETS - Assets Pledged to Counterparties (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | $ 3,719,906 | $ 3,584,354 |
Accrued interest receivable | 9,721 | 12,404 |
OtherReceivablesFromBrokerDealersAndClearingOrganizations | 414 | 0 |
Restricted cash | 79,363 | 84,885 |
Total Assets Pledged To Counterparties | 3,808,905 | 3,681,606 |
Repurchase Agreement [Member] | ||
Pledged Assets [Line Items] | ||
Restricted cash | 58,829 | 65,851 |
Total Assets Pledged To Counterparties | 3,788,371 | 3,662,572 |
Derivative [Member] | ||
Pledged Assets [Line Items] | ||
Restricted cash | 20,534 | 19,034 |
Total Assets Pledged To Counterparties | 20,534 | 19,034 |
Residential Mortgage Backed Securities [Member] | ||
Pledged Assets [Line Items] | ||
Accrued interest receivable | 9,636 | 12,367 |
Residential Mortgage Backed Securities [Member] | Pass Through Certificate [Member] | ||
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | 3,692,811 | 3,500,394 |
Residential Mortgage Backed Securities [Member] | Structured Finance [Member] | ||
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | 27,095 | 83,960 |
Residential Mortgage Backed Securities [Member] | Repurchase Agreement [Member] | ||
Pledged Assets [Line Items] | ||
Accrued interest receivable | 9,636 | 12,367 |
Residential Mortgage Backed Securities [Member] | Repurchase Agreement [Member] | Pass Through Certificate [Member] | ||
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | 3,692,811 | 3,500,394 |
Residential Mortgage Backed Securities [Member] | Repurchase Agreement [Member] | Structured Finance [Member] | ||
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | 27,095 | 83,960 |
Residential Mortgage Backed Securities [Member] | Derivative [Member] | ||
Pledged Assets [Line Items] | ||
Accrued interest receivable | 0 | 0 |
Residential Mortgage Backed Securities [Member] | Derivative [Member] | Pass Through Certificate [Member] | ||
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | 0 | 0 |
Residential Mortgage Backed Securities [Member] | Derivative [Member] | Structured Finance [Member] | ||
Pledged Assets [Line Items] | ||
Financial Instruments, Owned and Pledged as Collateral, at Fair Value | $ 0 | $ 0 |
PLEDGED ASSETS - Assets Pledg_2
PLEDGED ASSETS - Assets Pledged By Counterparties (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | $ 6,456 | $ 1,418 |
Cash | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 6,203 | 1,418 |
US Treasury Securities [Member] | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 253 | 0 |
Repurchase Agreement [Member] | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 373 | 1,418 |
Repurchase Agreement [Member] | Cash | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 120 | 1,418 |
Repurchase Agreement [Member] | US Treasury Securities [Member] | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 253 | 0 |
Derivative Agreements [Member] | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 6,083 | 0 |
Derivative Agreements [Member] | Cash | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | 6,083 | 0 |
Derivative Agreements [Member] | US Treasury Securities [Member] | ||
Pledged Assets [Line Items] | ||
Securities Pledged By Counterparties | $ 0 | $ 0 |
OFFSETTING ASSETS AND LIABILI_3
OFFSETTING ASSETS AND LIABILITIES - Offsetting of Assets (Details) $ in Thousands | Dec. 31, 2020USD ($) |
Offsetting Assets [Line Items] | |
Gross Amount Of Recognized Assets | $ 20,999 |
Gross Amount Of Assets Offset In The Balance Sheet | 0 |
Net Amount Of Assets Presented In The Balance Sheet | 20,999 |
Gross Amounts Of Financial Instruments Received Not Offset In Balance Sheet | 0 |
Gross Amounts Of Cash Collateral Received Not Offset In Balance Sheet | (6,083) |
Net Amount Of Assets | 14,916 |
Payer Swaption [Member] | |
Offsetting Assets [Line Items] | |
Gross Amount Of Recognized Assets | 17,433 |
Gross Amount Of Assets Offset In The Balance Sheet | 0 |
Net Amount Of Assets Presented In The Balance Sheet | 17,433 |
Gross Amounts Of Financial Instruments Received Not Offset In Balance Sheet | 0 |
Gross Amounts Of Cash Collateral Received Not Offset In Balance Sheet | (3,563) |
Net Amount Of Assets | 13,870 |
TBA Contracts [Member] | |
Offsetting Assets [Line Items] | |
Gross Amount Of Recognized Assets | 3,559 |
Gross Amount Of Assets Offset In The Balance Sheet | 0 |
Net Amount Of Assets Presented In The Balance Sheet | 3,559 |
Gross Amounts Of Financial Instruments Received Not Offset In Balance Sheet | 0 |
Gross Amounts Of Cash Collateral Received Not Offset In Balance Sheet | (2,520) |
Net Amount Of Assets | 1,039 |
Swap [Member] | |
Offsetting Assets [Line Items] | |
Gross Amount Of Recognized Assets | 7 |
Gross Amount Of Assets Offset In The Balance Sheet | 0 |
Net Amount Of Assets Presented In The Balance Sheet | 7 |
Gross Amounts Of Financial Instruments Received Not Offset In Balance Sheet | 0 |
Gross Amounts Of Cash Collateral Received Not Offset In Balance Sheet | 0 |
Net Amount Of Assets | $ 7 |
OFFSETTING ASSETS AND LIABILI_4
OFFSETTING ASSETS AND LIABILITIES - Offsetting of Liabilties (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Offsetting Liabilities [Line Items] | ||
Gross Amount Of Recognized Liabilties | $ 3,628,813 | $ 3,468,764 |
Gross Amount Of Liabilties Offset In The Balance Sheet | 0 | 0 |
Net Amount Of Liabilities Presented In The Balance Sheet | 3,628,813 | 3,468,764 |
Gross Amount Of Financial Instruments Posted Not Offset in Balance Sheet | (3,536,757) | (3,382,255) |
Gross Amounts Of Cash Posted Not Offset In Balance Sheet | (78,874) | (83,547) |
Net Amount Of Liabilities | 5,452 | 2,962 |
Repurchase Agreement [Member] | ||
Offsetting Liabilities [Line Items] | ||
Gross Amount Of Recognized Liabilties | 3,595,586 | 3,448,106 |
Gross Amount Of Liabilties Offset In The Balance Sheet | 0 | 0 |
Net Amount Of Liabilities Presented In The Balance Sheet | 3,595,586 | 3,448,106 |
Gross Amount Of Financial Instruments Posted Not Offset in Balance Sheet | (3,536,757) | (3,382,255) |
Gross Amounts Of Cash Posted Not Offset In Balance Sheet | (58,829) | (65,851) |
Net Amount Of Liabilities | 0 | 0 |
Swap [Member] | ||
Offsetting Liabilities [Line Items] | ||
Gross Amount Of Recognized Liabilties | 24,711 | 20,146 |
Gross Amount Of Liabilties Offset In The Balance Sheet | 0 | 0 |
Net Amount Of Liabilities Presented In The Balance Sheet | 24,711 | 20,146 |
Gross Amount Of Financial Instruments Posted Not Offset in Balance Sheet | 0 | 0 |
Gross Amounts Of Cash Posted Not Offset In Balance Sheet | (19,761) | (17,450) |
Net Amount Of Liabilities | 4,950 | 2,696 |
TBA securities [Member] | ||
Offsetting Liabilities [Line Items] | ||
Gross Amount Of Recognized Liabilties | 786 | 512 |
Gross Amount Of Liabilties Offset In The Balance Sheet | 0 | 0 |
Net Amount Of Liabilities Presented In The Balance Sheet | 786 | 512 |
Gross Amount Of Financial Instruments Posted Not Offset in Balance Sheet | 0 | 0 |
Gross Amounts Of Cash Posted Not Offset In Balance Sheet | (284) | (246) |
Net Amount Of Liabilities | 502 | $ 266 |
Payer Swaption [Member] | ||
Offsetting Liabilities [Line Items] | ||
Gross Amount Of Recognized Liabilties | 7,730 | |
Gross Amount Of Liabilties Offset In The Balance Sheet | 0 | |
Net Amount Of Liabilities Presented In The Balance Sheet | 7,730 | |
Gross Amount Of Financial Instruments Posted Not Offset in Balance Sheet | 0 | |
Gross Amounts Of Cash Posted Not Offset In Balance Sheet | 0 | |
Net Amount Of Liabilities | $ 0 |
CAPITAL STOCK - Completed publi
CAPITAL STOCK - Completed public offerings ofcommon stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2020 | Sep. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | |
Stock Issued During Period Shares New Issues | 13,019,240 | 14,377,126 | ||||||
Stock Issued During Period, Value, New Issues | $ 71,050 | $ 92,314 | ||||||
At the Market Offering Program [Member] | ||||||||
Weighted Average Price Received Per Share | $ 5.41 | $ 5.15 | $ 6.23 | $ 6.37 | $ 6.70 | $ 6.84 | $ 5.41 | |
Stock Issued During Period Shares New Issues | 6,775,187 | 3,073,326 | 3,170,727 | 1,771,301 | 4,337,931 | 1,267,894 | ||
Stock Issued During Period, Value, New Issues | $ 36,037 | $ 15,566 | $ 19,447 | $ 11,098 | $ 28,495 | $ 8,503 | ||
Follow-on Offering [Member] | ||||||||
Weighted Average Price Received Per Share | $ 6.35 | |||||||
Stock Issued During Period Shares New Issues | 7,000,000 | |||||||
Stock Issued During Period, Value, New Issues | $ 44,218 |
CAPITAL STOCK - Share Repurchas
CAPITAL STOCK - Share Repurchase Progam (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | 65 Months Ended | ||||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2020 | Feb. 08, 2018 | Jul. 29, 2015 | |
Share Repurchase Program [Line Items] | ||||||
Stock Repurchased and Retired During Period, Shares | 19,891 | 470,000 | 3,979,000 | |||
Stock Repurchased and Retired During Period, Value | $ (68) | $ (3,024) | $ (26,423) | |||
Share Repurchase Program [Member] | Common Stock [Member] | ||||||
Share Repurchase Program [Line Items] | ||||||
Stock Repurchased and Retired During Period, Shares | 19,891 | 469,975 | 3,979,402 | 5,685,511 | ||
Stock Repurchased and Retired During Period, Value | $ 100 | $ 3,000 | $ 26,400 | $ 40,400 | ||
Weighted Average Share Repurchase Price | $ 3.42 | $ 6.43 | $ 6.64 | $ 7.10 | ||
Share Repurchase Program [Member] | Maximum [Member] | Common Stock [Member] | ||||||
Share Repurchase Program [Line Items] | ||||||
Share Repurchase | 2,000,000 | |||||
Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased | 837,311 | 837,311 | 783,757 | |||
Program Increase [Member] | Maximum [Member] | Common Stock [Member] | ||||||
Share Repurchase Program [Line Items] | ||||||
Share Repurchase | 4,522,822 | |||||
Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased | 5,306,579 |
CAPITAL STOCK - Cash dividends
CAPITAL STOCK - Cash dividends declared (Details) - USD ($) $ / shares in Units, $ in Thousands | 2 Months Ended | 3 Months Ended | 12 Months Ended | 95 Months Ended | ||||||||||||||
Feb. 26, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2020 | |
Dividends Payable [Line Items] | ||||||||||||||||||
Per Share Amount | $ 0.195 | $ 0.190 | $ 0.165 | $ 0.240 | $ 0.24 | $ 0.24 | $ 0.24 | $ 0.24 | $ 0.79 | $ 0.96 | $ 1.07 | |||||||
Dividend Declared [Member] | ||||||||||||||||||
Dividends Payable [Line Items] | ||||||||||||||||||
Per Share Amount | $ 0.790 | $ 0.960 | $ 1.070 | $ 1.680 | $ 1.680 | $ 1.920 | $ 2.160 | $ 1.395 | $ 11.785 | |||||||||
Total | $ 53,570 | $ 54,421 | $ 55,814 | $ 70,717 | $ 41,388 | $ 38,748 | $ 22,643 | $ 4,662 | $ 353,042 | |||||||||
Dividend Declared [Member] | Subsequent Event [Member] | ||||||||||||||||||
Dividends Payable [Line Items] | ||||||||||||||||||
Per Share Amount | $ 0.130 | |||||||||||||||||
Total | $ 11,079 |
STOCK INCENTIVE PLAN - Descript
STOCK INCENTIVE PLAN - Descriptions of Plans (Details) | 12 Months Ended |
Dec. 31, 2020shares | |
Employee Benefits And Share Based Compensation [Abstract] | |
Maximum Number of Shares to Be Issued the Plan | 4,000,000 |
Percentage of Outstanding Stock Limitation | 10.00% |
STOCK INCENTIVE PLAN - (Narrati
STOCK INCENTIVE PLAN - (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Performance Shares [Member] | ||
Incentive Share Activity, Shares | ||
Nonvested - Beginning Balance | 19,021 | 43,672 |
Forfeited | 1,607 | 0 |
Vested | 12,860 | 24,651 |
Nonvested - Ending Balance | 4,554 | 19,021 |
Incentive Share Activity, Grant Date Fair Value | ||
Nonvested - Beginning Balance | $ 7.78 | $ 8.34 |
Forfeited | 7.45 | 0 |
Vested | 7.93 | 8.78 |
Nonvested - Ending Balance | $ 7.45 | $ 7.78 |
Intrinsic Value of Nonvested | $ 24 | $ 111 |
Weighted Average Remaining Term | 4 months 24 days | 9 months 18 days |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $ 4 | $ 42 |
Share Based Compensation | $ 38 | $ 115 |
Deferred Stock Units [Member] | ||
Incentive Share Activity, Shares | ||
Nonvested - Beginning Balance | 43,570 | 12,434 |
Granted | 47,376 | 31,136 |
Nonvested - Ending Balance | 90,946 | 43,570 |
Incentive Share Activity, Grant Date Fair Value | ||
Nonvested - Beginning Balance | $ 6.56 | $ 7.37 |
Granted | 4.41 | 6.23 |
Nonvested - Ending Balance | $ 5.44 | $ 6.56 |
Intrinsic Value of Nonvested | $ 473 | $ 255 |
Share Based Compensation | $ 180 | $ 180 |
EARNINGS PER SHARE (Details)
EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] | |||||||||||
Net Income (Loss) Available to Common Stockholders, Basic | $ 2,128 | $ 24,265 | $ (44,387) | ||||||||
Weighted Average Number of Shares Outstanding, Diluted [Abstract] | |||||||||||
Common Shares Outstanding | 76,073,000 | 63,062,000 | 49,132,000 | ||||||||
Unvested Dividend Eligible Shares Outstanding at the Balance Sheet Date | 96,000 | 63,000 | 0 | ||||||||
Effect of Weighting | (8,958,000) | (6,797,000) | 3,066,000 | ||||||||
Weighted Average Shares - Basic and Diluted | 70,497,000 | 67,302,000 | 66,310,000 | 64,590,000 | 63,124,000 | 60,419,000 | 52,601,000 | 48,905,000 | 67,210,815 | 56,328,027 | 52,198,175 |
Income (Loss) Per Share - Basic and Diluted | $ 0.23 | $ 0.42 | $ 0.74 | $ (1.41) | $ 0.29 | $ (0.14) | $ 0.07 | $ 0.22 | $ 0.03 | $ 0.43 | $ (0.85) |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | 0 | 56,000 |
FAIR VALUE - Assets - Assets a
FAIR VALUE - Assets - Assets and Liabilities Recorded at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mortgage-backed securities | $ 3,726,895 | $ 3,590,921 |
Derivative, Fair Value, Net | 20,999 | 0 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mortgage-backed securities | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Swap [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Interest Rate Swaption [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 0 | |
Fair Value, Inputs, Level 1 [Member] | TBA Contracts [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mortgage-backed securities | 3,726,895 | 3,590,921 |
Fair Value, Inputs, Level 2 [Member] | Swap [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | (24,704) | (20,146) |
Fair Value, Inputs, Level 2 [Member] | Interest Rate Swaption [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 9,703 | |
Fair Value, Inputs, Level 2 [Member] | TBA Contracts [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 2,773 | (512) |
Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Mortgage-backed securities | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Swap [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Interest Rate Swaption [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | 0 | |
Fair Value, Inputs, Level 3 [Member] | TBA Contracts [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative, Fair Value, Net | $ 0 | $ 0 |
RELATED PARTY TRANSACTIONS - Ma
RELATED PARTY TRANSACTIONS - Management Agreement (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Related Party Transaction [Line Items] | |||
Due to affiliates | $ 632 | $ 622 | |
Bimini Advisors, LLC [Member] | |||
Related Party Transaction [Line Items] | |||
Termination Date | February 20, 2022 | ||
Automatic Renewal Period Of Management Agreement | 1 year | ||
Management Fees And Allocated Expenses | $ 6,800 | $ 6,900 | $ 7,800 |
RELATED PARTY TRANSACTIONS - Ot
RELATED PARTY TRANSACTIONS - Other Relationships (Narrative) (Details) - Bimini Capital Management Inc [Member] | Dec. 31, 2020shares |
Related Party Transaction [Line Items] | |
Orchid Shares Owned | 2,595,357 |
Entity Ownership Percentage | 3.40% |
QUARTERLY RESULTS - (Details)
QUARTERLY RESULTS - (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Quarterly Financial Information Disclosure [Abstract] | |||||||||||
Interest Income | $ 25,893 | $ 27,223 | $ 27,258 | $ 35,671 | $ 37,529 | $ 35,907 | $ 36,455 | $ 32,433 | |||
Repurchase Agreements Interest Expense Amount | 2,011 | 2,043 | 4,479 | 16,523 | 20,022 | 22,321 | 22,431 | 18,892 | $ 25,056 | $ 83,666 | $ 70,360 |
Net Interest Income | 23,882 | 25,180 | 22,779 | 19,148 | 17,507 | 13,586 | 14,024 | 13,541 | |||
Realized And Unrealized Gains | (4,605) | 5,745 | 28,749 | (108,206) | 3,841 | (19,431) | (7,670) | (748) | |||
Portfolio Income | 19,277 | 30,925 | 51,528 | (89,058) | 21,348 | (5,845) | 6,354 | 12,793 | |||
Management Fees | 1,826 | 1,629 | 1,616 | 1,724 | 1,856 | 1,791 | 1,653 | 1,608 | |||
Other Expenses | 972 | 1,220 | 1,140 | 417 | 880 | 841 | 1,168 | 588 | |||
CostsAndExpenses | 2,798 | 2,849 | 2,756 | 2,141 | 2,736 | 2,632 | 2,821 | 2,196 | |||
Net Income Loss | $ 16,479 | $ 28,076 | $ 48,772 | $ (91,199) | $ 18,612 | $ (8,477) | $ 3,533 | $ 10,597 | |||
Earnings Per Share Diluted | $ 0.23 | $ 0.42 | $ 0.73 | $ (1.41) | $ 0.29 | $ (0.14) | $ 0.07 | $ 0.22 | |||
Weighted Average Number Of Basic Shares Outstanding | 70,497,000 | 67,302,000 | 66,310,000 | 64,590,000 | 63,124,000 | 60,419,000 | 52,601,000 | 48,905,000 | 67,210,815 | 56,328,027 | 52,198,175 |
Dividends Declared Per Common Share | $ 0.195 | $ 0.190 | $ 0.165 | $ 0.240 | $ 0.24 | $ 0.24 | $ 0.24 | $ 0.24 | $ 0.79 | $ 0.96 | $ 1.07 |
SUBSEQUENT EVENTS - (Details)
SUBSEQUENT EVENTS - (Details) - USD ($) $ / shares in Units, $ in Thousands | Jan. 25, 2021 | Aug. 02, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Subsidiary, Sale of Stock [Line Items] | |||||
Proceeds From Issuance Of Common Stock | $ 71,050 | $ 92,314 | $ 0 | ||
Stock Issued During Period, Value, New Issues | $ 71,050 | $ 92,314 | |||
Stock Issued During Period Shares New Issues | 13,019,240 | 14,377,126 | |||
Follow-on Offering [Member] | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Proceeds From Issuance Of Common Stock | $ 45,300 | $ 44,200 | |||
Stock Issued During Period Shares New Issues | 8,740,000 | 7,000,000 | |||
Share Price | $ 5.20 | $ 6.3535 | |||
Follow-on Offering [Member] | Original Offering Terms [Member] | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Stock Issued During Period Shares New Issues | 7,600,000 | ||||
Follow-on Offering [Member] | Offering Option Terms [Member] | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Stock Issued During Period Shares New Issues | 1,140,000 |